<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" returnVersion="2022v5.0">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2023-12-14T13:38:03+00:00</ReturnTs>
    <TaxPeriodEndDt>2023-03-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>346565596</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>ERNST &amp; YOUNG US LLP</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>1901 SIXTH AVENUE NORTH</AddressLine1Txt>
        <CityNm>BIRMINGHAM</CityNm>
        <StateAbbreviationCd>AL</StateAbbreviationCd>
        <ZIPCd>35203</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2022-04-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>751835298</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>The Susan G Komen Breast Cancer Foundation Inc</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>SUSA</BusinessNameControlTxt>
      <PhoneNum>9728551600</PhoneNum>
      <USAddress>
        <AddressLine1Txt>13770 NOEL ROAD SUITE 801889</AddressLine1Txt>
        <CityNm>DALLAS</CityNm>
        <StateAbbreviationCd>TX</StateAbbreviationCd>
        <ZIPCd>75380</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>PAULA SUE SCHNEIDER</PersonNm>
      <PersonTitleTxt>PRESIDENT AND CEO</PersonTitleTxt>
      <PhoneNum>9728551600</PhoneNum>
      <SignatureDt>2023-12-14</SignatureDt>
      <DiscussWithPaidPreparerInd>true</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>PAULA</PersonFirstNm>
        <PersonLastNm>SCHNEIDER</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>true</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>Kathy Pitts</PreparerPersonNm>
      <PTIN>P00292940</PTIN>
      <PhoneNum>2052512000</PhoneNum>
    </PreparerPersonGrp>
    <TaxYr>2022</TaxYr>
    <BuildTS>2023-04-26 12:10:37Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="11">
    <IRS990 documentId="IRS990" softwareId="22016089" softwareVersionNum="2022v5.0">
      <DoingBusinessAsName>
        <BusinessNameLine1Txt>SUSAN G KOMEN</BusinessNameLine1Txt>
      </DoingBusinessAsName>
      <PrincipalOfcrBusinessName>
        <BusinessNameLine1Txt>PAULA SUE SCHNEIDER</BusinessNameLine1Txt>
      </PrincipalOfcrBusinessName>
      <USAddress>
        <AddressLine1Txt>13770 NOEL ROAD SUITE 801889</AddressLine1Txt>
        <CityNm>DALLAS</CityNm>
        <StateAbbreviationCd>TX</StateAbbreviationCd>
        <ZIPCd>75380</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>118544114</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>false</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.KOMEN.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1982</FormationYr>
      <LegalDomicileStateCd>TX</LegalDomicileStateCd>
      <ActivityOrMissionDesc>OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAK-THROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>19</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>19</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>468</TotalEmployeeCnt>
      <TotalVolunteersCnt>7089</TotalVolunteersCnt>
      <TotalGrossUBIAmt>6104</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>99456148</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>111805407</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>2500</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>7437450</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>2453577</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>4365358</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>-6661279</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>111261456</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>107597705</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>25691669</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>29280228</CYGrantsAndSimilarPaidAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>36149496</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>45865289</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>1181706</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>1363728</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>27230240</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>37609513</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>40554624</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>100632384</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>117063869</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>10629072</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>-9466164</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>207354061</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>192631082</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>59717916</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>62957218</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>147636145</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>129673864</NetAssetsOrFundBalancesEOYAmt>
      <MissionDesc>SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES FROM BREAST CANCER BY FINDING BREAKTHROUGHS TO PREVENT, DETECT, TREAT, AND CURE BREAST CANCER, AND BY MEETING THE MOST CRITICAL NEEDS IN COMMUNITIES TO ENSURE EVERYONE GETS THE BREAST CANCER CARE THEY NEED WHEN THEY NEED IT.</MissionDesc>
      <SignificantNewProgramSrvcInd>false</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>false</SignificantChangeInd>
      <ExpenseAmt>48712358</ExpenseAmt>
      <GrantAmt>10610338</GrantAmt>
      <RevenueAmt>0</RevenueAmt>
      <Desc>PATIENT CARE: PROVISION OF BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS, THIRD-PARTY CONTRACTS AND DIRECTLY BY KOMEN, WITH SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS.</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>24634101</ExpenseAmt>
        <GrantAmt>18669890</GrantAmt>
        <RevenueAmt>0</RevenueAmt>
        <Desc>GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; NEW STRATEGIES TO TREAT, DETECT, AND PREDICT RISK OF BREAST CANCER, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES. SEE SCHEDULE O FOR ADDITIONAL DETAILS.</Desc>
      </ProgSrvcAccomActy2Grp>
      <ProgSrvcAccomActy3Grp>
        <ExpenseAmt>3359841</ExpenseAmt>
        <GrantAmt>0</GrantAmt>
        <RevenueAmt>0</RevenueAmt>
        <Desc>PUBLIC POLICY AND ADVOCACY: INITIATIVES THAT HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER, INCLUDING ACTIVITIES ADVOCATING FOR LEGISLATIVE, REGULATORY AND OTHER POLICY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE, AND FUND CRITICAL BREAST CANCER RESEARCH. SEE SCHEDULE O FOR DETAILS.</Desc>
      </ProgSrvcAccomActy3Grp>
      <TotalProgramServiceExpensesAmt>76706300</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="IRS990ScheduleA">true</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="IRS990ScheduleB">true</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>false</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd referenceDocumentId="IRS990ScheduleC">true</LobbyingActivitiesInd>
      <DonorAdvisedFundInd>false</DonorAdvisedFundInd>
      <ConservationEasementsInd>false</ConservationEasementsInd>
      <CollectionsOfArtInd>false</CollectionsOfArtInd>
      <CreditCounselingInd>false</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd referenceDocumentId="IRS990ScheduleD">true</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="IRS990ScheduleD">true</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="IRS990ScheduleD">true</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd>false</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd>false</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd>false</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="IRS990ScheduleD">true</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd>false</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">true</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>false</SchoolOperatingInd>
      <ForeignOfficeInd>false</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="IRS990ScheduleF">true</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="IRS990ScheduleF">true</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd>false</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd referenceDocumentId="IRS990ScheduleG">true</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd referenceDocumentId="IRS990ScheduleG">true</FundraisingActivitiesInd>
      <GamingActivitiesInd>false</GamingActivitiesInd>
      <OperateHospitalInd>false</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="IRS990ScheduleI">true</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="IRS990ScheduleI">true</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="IRS990ScheduleJ">true</ScheduleJRequiredInd>
      <TaxExemptBondsInd>false</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>false</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>false</PYExcessBenefitTransInd>
      <LoanOutstandingInd>false</LoanOutstandingInd>
      <GrantToRelatedPersonInd>false</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>false</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>false</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>false</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd referenceDocumentId="IRS990ScheduleM">true</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>false</DeductibleArtContributionInd>
      <TerminateOperationsInd>false</TerminateOperationsInd>
      <PartialLiquidationInd>false</PartialLiquidationInd>
      <DisregardedEntityInd>false</DisregardedEntityInd>
      <RelatedEntityInd>false</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>false</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>false</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>false</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>true</ScheduleORequiredInd>
      <IRPDocumentCnt>193</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>true</BackupWthldComplianceInd>
      <EmployeeCnt>468</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>true</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>true</UnrelatedBusIncmOverLimitInd>
      <Form990TFiledInd>true</Form990TFiledInd>
      <ForeignFinancialAccountInd>false</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>false</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>false</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>false</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>true</QuidProQuoContributionsInd>
      <QuidProQuoContriDisclInd>true</QuidProQuoContriDisclInd>
      <Form8282PropertyDisposedOfInd>true</Form8282PropertyDisposedOfInd>
      <Form8282FiledCnt>2</Form8282FiledCnt>
      <RcvFndsToPayPrsnlBnftCntrctInd>false</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>false</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>false</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>false</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>false</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>19</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>19</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>false</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>false</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>false</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>false</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>false</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>false</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>false</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>true</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>true</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>false</OfficerMailingAddressInd>
      <LocalChaptersInd>true</LocalChaptersInd>
      <PoliciesReferenceChaptersInd>true</PoliciesReferenceChaptersInd>
      <Form990ProvidedToGvrnBodyInd>true</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>true</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>true</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>true</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>true</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>true</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>true</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>true</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>false</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>CA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>DC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>FL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>GA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>HI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>LA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ME</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MD</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NJ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NM</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ND</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AZ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>RI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>SC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>TN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>UT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WI</StatesWhereCopyOfReturnIsFldCd>
      <OwnWebsiteInd>X</OwnWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <BusinessName>
          <BusinessNameLine1Txt>RIA WILLIAMS</BusinessNameLine1Txt>
        </BusinessName>
        <PhoneNum>9728551600</PhoneNum>
        <USAddress>
          <AddressLine1Txt>13770 NOEL ROAD SUITE 801889</AddressLine1Txt>
          <CityNm>DALLAS</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>75380</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Ed Dandridge</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>Chair of the Board</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Jerri Johnson</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD MEMBER (VICE CHAIR)</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Andi Owen</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member (ending March 2023)</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BJ Schaknowski</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Boris Dolgonos</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member (beginning March 2023)</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Christina Minnis</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Gail Heimann</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>John O'Neill</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member (ended April 2022)</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Julia Harris</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Julie Gruber</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Kristen Racich</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>LaQuenta Jacobs</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member (beginning March 2023)</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Luke Sauter</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Lydia The</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Michelle Bottomley</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Peter Brundage</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Renee Baker</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOAD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Robyn Shepherd</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Sean Slovenski</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Traci Blunt</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Valerie Rainey</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>BOD Member (beginning March 2023)</TitleTxt>
        <AverageHoursPerWeekRt>1.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Eunice Nakamura</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>General Counsel and Corporate Secretary</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>273878</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>23687</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Paula Schneider</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>President and CEO</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>888164</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>27615</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Ria Williams</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>Chief Fin &amp; Ops Officer</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>319076</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>30635</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Catherine Olivieri</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>SVP, Human Resources</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>277075</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>26419</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Lori Maris</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>SVP, OPS SERVICES &amp; SUPPORT</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>240233</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>15349</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Victoria Smart</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>SVP, Mission</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>331477</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>15705</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Catherine Stone</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Community Health</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>213060</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>13131</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Kari Bodell</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Development Programs Strategy</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>239625</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>14169</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Michelle Strong</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Marketing Strategy</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>233180</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>22360</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Sarah Rosales</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Corporate Partnerships</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>257358</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>29351</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Srinivasu Avadhanula</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, BI Platform &amp; Engineering</TitleTxt>
        <AverageHoursPerWeekRt>55.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>249792</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>23614</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Dana Brown</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>Chief Operating Officer (Term 3/31/22)</TitleTxt>
        <AverageHoursPerWeekRt>0.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <FormerOfcrDirectorTrusteeInd>X</FormerOfcrDirectorTrusteeInd>
        <ReportableCompFromOrgAmt>184757</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>5580</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>3707675</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>247615</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>116</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>false</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>true</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>false</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>Event 360</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>205 N Michigan Ave</AddressLine1Txt>
            <CityNm>Chicago</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60601</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Event Management</ServicesDesc>
        <CompensationAmt>3132937</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>RKD Group LLC</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>3400 Waterview Parkway</AddressLine1Txt>
            <CityNm>Richardson</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75080</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Consulting</ServicesDesc>
        <CompensationAmt>1014986</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>Prometheus Research LLC</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>One Audubon Street</AddressLine1Txt>
            <AddressLine2Txt>4th Fllor</AddressLine2Txt>
            <CityNm>New Haven</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06511</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Technology Services</ServicesDesc>
        <CompensationAmt>460000</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>MSB Financial Solutions LLC</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>79 Cherrywood Dr</AddressLine1Txt>
            <CityNm>Nashua</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03062</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Software Services</ServicesDesc>
        <CompensationAmt>445942</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>Ernst &amp; Young</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>3712 Solutions Center</AddressLine1Txt>
            <CityNm>Chicago</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60677</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Acctg &amp; Tax Services</ServicesDesc>
        <CompensationAmt>342243</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>17</CntrctRcvdGreaterThan100KCnt>
      <FederatedCampaignsAmt>432565</FederatedCampaignsAmt>
      <MembershipDuesAmt>0</MembershipDuesAmt>
      <FundraisingAmt>35668334</FundraisingAmt>
      <RelatedOrganizationsAmt>0</RelatedOrganizationsAmt>
      <GovernmentGrantsAmt>0</GovernmentGrantsAmt>
      <AllOtherContributionsAmt>75704508</AllOtherContributionsAmt>
      <NoncashContributionsAmt>592477</NoncashContributionsAmt>
      <TotalContributionsAmt>111805407</TotalContributionsAmt>
      <TotalOthProgramServiceRevGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </TotalOthProgramServiceRevGrp>
      <TotalProgramServiceRevenueAmt>0</TotalProgramServiceRevenueAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>1438781</TotalRevenueColumnAmt>
        <ExclusionAmt>1438781</ExclusionAmt>
      </InvestmentIncomeGrp>
      <IncmFromInvestBondProceedsGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </IncmFromInvestBondProceedsGrp>
      <RoyaltiesRevenueGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </RoyaltiesRevenueGrp>
      <GrossRentsGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </GrossRentsGrp>
      <LessRentalExpensesGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </LessRentalExpensesGrp>
      <RentalIncomeOrLossGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </RentalIncomeOrLossGrp>
      <NetRentalIncomeOrLossGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </NetRentalIncomeOrLossGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>3316237</SecuritiesAmt>
        <OtherAmt>0</OtherAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>2301441</SecuritiesAmt>
        <OtherAmt>0</OtherAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>1014796</SecuritiesAmt>
        <OtherAmt>0</OtherAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>1014796</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>1014796</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <FundraisingGrossIncomeAmt>1820234</FundraisingGrossIncomeAmt>
      <ContriRptFundraisingEventAmt>35668334</ContriRptFundraisingEventAmt>
      <FundraisingDirectExpensesAmt>8533874</FundraisingDirectExpensesAmt>
      <NetIncmFromFundraisingEvtGrp>
        <TotalRevenueColumnAmt>-6713640</TotalRevenueColumnAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>-6713640</ExclusionAmt>
      </NetIncmFromFundraisingEvtGrp>
      <GamingGrossIncomeAmt>29627</GamingGrossIncomeAmt>
      <GamingDirectExpensesAmt>45162</GamingDirectExpensesAmt>
      <NetIncomeFromGamingGrp>
        <TotalRevenueColumnAmt>-15535</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>-15535</ExclusionAmt>
      </NetIncomeFromGamingGrp>
      <GrossSalesOfInventoryAmt>107070</GrossSalesOfInventoryAmt>
      <CostOfGoodsSoldAmt>65932</CostOfGoodsSoldAmt>
      <NetIncomeOrLossGrp>
        <TotalRevenueColumnAmt>41138</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>41138</ExclusionAmt>
      </NetIncomeOrLossGrp>
      <OtherRevenueMiscGrp>
        <Desc>OTHER INCOME</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>26758</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>6104</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>20654</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueMiscGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueMiscGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <MiscellaneousRevenueGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </MiscellaneousRevenueGrp>
      <OtherRevenueTotalAmt>26758</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>107597705</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>6104</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>-4213806</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>19635695</TotalAmt>
        <ProgramServicesAmt>19635695</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <GrantsToDomesticIndividualsGrp>
        <TotalAmt>9078750</TotalAmt>
        <ProgramServicesAmt>9078750</ProgramServicesAmt>
      </GrantsToDomesticIndividualsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>565783</TotalAmt>
        <ProgramServicesAmt>565783</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <BenefitsToMembersGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
      </BenefitsToMembersGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>2482405</TotalAmt>
        <ProgramServicesAmt>1282179</ProgramServicesAmt>
        <ManagementAndGeneralAmt>538632</ManagementAndGeneralAmt>
        <FundraisingAmt>661594</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <CompDisqualPersonsGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </CompDisqualPersonsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>36277286</TotalAmt>
        <ProgramServicesAmt>18726067</ProgramServicesAmt>
        <ManagementAndGeneralAmt>7828981</ManagementAndGeneralAmt>
        <FundraisingAmt>9722238</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>1479554</TotalAmt>
        <ProgramServicesAmt>779973</ProgramServicesAmt>
        <ManagementAndGeneralAmt>303129</ManagementAndGeneralAmt>
        <FundraisingAmt>396452</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>3014565</TotalAmt>
        <ProgramServicesAmt>1502541</ProgramServicesAmt>
        <ManagementAndGeneralAmt>748043</ManagementAndGeneralAmt>
        <FundraisingAmt>763981</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>2611479</TotalAmt>
        <ProgramServicesAmt>1337671</ProgramServicesAmt>
        <ManagementAndGeneralAmt>560570</ManagementAndGeneralAmt>
        <FundraisingAmt>713238</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesManagementGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesManagementGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>150411</TotalAmt>
        <ProgramServicesAmt>60819</ProgramServicesAmt>
        <ManagementAndGeneralAmt>29864</ManagementAndGeneralAmt>
        <FundraisingAmt>59728</FundraisingAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>342030</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>342030</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesAccountingGrp>
      <FeesForServicesLobbyingGrp>
        <TotalAmt>293520</TotalAmt>
        <ProgramServicesAmt>293520</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesLobbyingGrp>
      <FeesForServicesProfFundraising>
        <TotalAmt>1363728</TotalAmt>
        <FundraisingAmt>1363728</FundraisingAmt>
      </FeesForServicesProfFundraising>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>5738163</TotalAmt>
        <ProgramServicesAmt>3331081</ProgramServicesAmt>
        <ManagementAndGeneralAmt>198565</ManagementAndGeneralAmt>
        <FundraisingAmt>2208517</FundraisingAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>16194959</TotalAmt>
        <ProgramServicesAmt>8190560</ProgramServicesAmt>
        <ManagementAndGeneralAmt>162466</ManagementAndGeneralAmt>
        <FundraisingAmt>7841933</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>2065603</TotalAmt>
        <ProgramServicesAmt>846897</ProgramServicesAmt>
        <ManagementAndGeneralAmt>619681</ManagementAndGeneralAmt>
        <FundraisingAmt>599025</FundraisingAmt>
      </InformationTechnologyGrp>
      <RoyaltiesGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </RoyaltiesGrp>
      <OccupancyGrp>
        <TotalAmt>174523</TotalAmt>
        <ProgramServicesAmt>107985</ProgramServicesAmt>
        <ManagementAndGeneralAmt>29887</ManagementAndGeneralAmt>
        <FundraisingAmt>36651</FundraisingAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>1194739</TotalAmt>
        <ProgramServicesAmt>589628</ProgramServicesAmt>
        <ManagementAndGeneralAmt>341009</ManagementAndGeneralAmt>
        <FundraisingAmt>264102</FundraisingAmt>
      </TravelGrp>
      <PymtTravelEntrtnmntPubOfclGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </PymtTravelEntrtnmntPubOfclGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>224153</TotalAmt>
        <ProgramServicesAmt>97027</ProgramServicesAmt>
        <ManagementAndGeneralAmt>95686</ManagementAndGeneralAmt>
        <FundraisingAmt>31440</FundraisingAmt>
      </ConferencesMeetingsGrp>
      <InterestGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </InterestGrp>
      <PaymentsToAffiliatesGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </PaymentsToAffiliatesGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>1162453</TotalAmt>
        <ProgramServicesAmt>904513</ProgramServicesAmt>
        <ManagementAndGeneralAmt>135072</ManagementAndGeneralAmt>
        <FundraisingAmt>122868</FundraisingAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>499600</TotalAmt>
        <ProgramServicesAmt>499600</ProgramServicesAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>CONSULT &amp; PROF. FEES</Desc>
        <TotalAmt>6582084</TotalAmt>
        <ProgramServicesAmt>5401593</ProgramServicesAmt>
        <ManagementAndGeneralAmt>389052</ManagementAndGeneralAmt>
        <FundraisingAmt>791439</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>EQUIP RENTAL &amp; MAINT</Desc>
        <TotalAmt>3127554</TotalAmt>
        <ProgramServicesAmt>2008073</ProgramServicesAmt>
        <ManagementAndGeneralAmt>401706</ManagementAndGeneralAmt>
        <FundraisingAmt>717775</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>MERCHANT SERVICES &amp; BANK FEES</Desc>
        <TotalAmt>1765647</TotalAmt>
        <ProgramServicesAmt>1022682</ProgramServicesAmt>
        <ManagementAndGeneralAmt>105221</ManagementAndGeneralAmt>
        <FundraisingAmt>637744</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>EVENT PRODUCTION</Desc>
        <TotalAmt>235470</TotalAmt>
        <ProgramServicesAmt>113585</ProgramServicesAmt>
        <ManagementAndGeneralAmt>14066</ManagementAndGeneralAmt>
        <FundraisingAmt>107819</FundraisingAmt>
      </OtherExpensesGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>803715</TotalAmt>
        <ProgramServicesAmt>330078</ProgramServicesAmt>
        <ManagementAndGeneralAmt>283669</ManagementAndGeneralAmt>
        <FundraisingAmt>189968</FundraisingAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>117063869</TotalAmt>
        <ProgramServicesAmt>76706300</ProgramServicesAmt>
        <ManagementAndGeneralAmt>13127329</ManagementAndGeneralAmt>
        <FundraisingAmt>27230240</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <TotalJointCostsGrp>
        <TotalAmt>48508025</TotalAmt>
        <ProgramServicesAmt>24374495</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1206569</ManagementAndGeneralAmt>
        <FundraisingAmt>22926961</FundraisingAmt>
      </TotalJointCostsGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>23067395</BOYAmt>
        <EOYAmt>11205049</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>15045253</BOYAmt>
        <EOYAmt>15405966</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <AccountsReceivableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </AccountsReceivableGrp>
      <ReceivablesFromOfficersEtcGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </ReceivablesFromOfficersEtcGrp>
      <RcvblFromDisqualifiedPrsnGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </RcvblFromDisqualifiedPrsnGrp>
      <OthNotesLoansReceivableNetGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OthNotesLoansReceivableNetGrp>
      <InventoriesForSaleOrUseGrp>
        <BOYAmt>9577</BOYAmt>
        <EOYAmt>47380</EOYAmt>
      </InventoriesForSaleOrUseGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>2120424</BOYAmt>
        <EOYAmt>1613365</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>13932941</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>9579406</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>3645471</BOYAmt>
        <EOYAmt>4353535</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>119988473</BOYAmt>
        <EOYAmt>114281787</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <InvestmentsOtherSecuritiesGrp>
        <BOYAmt>43470000</BOYAmt>
        <EOYAmt>43470000</EOYAmt>
      </InvestmentsOtherSecuritiesGrp>
      <InvestmentsProgramRelatedGrp>
        <BOYAmt>0</BOYAmt>
      </InvestmentsProgramRelatedGrp>
      <IntangibleAssetsGrp>
        <BOYAmt>0</BOYAmt>
      </IntangibleAssetsGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>7468</BOYAmt>
        <EOYAmt>2254000</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>207354061</BOYAmt>
        <EOYAmt>192631082</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>9791057</BOYAmt>
        <EOYAmt>9306708</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>49697151</BOYAmt>
        <EOYAmt>53366811</EOYAmt>
      </GrantsPayableGrp>
      <DeferredRevenueGrp>
        <BOYAmt>229708</BOYAmt>
        <EOYAmt>283699</EOYAmt>
      </DeferredRevenueGrp>
      <TaxExemptBondLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </TaxExemptBondLiabilitiesGrp>
      <EscrowAccountLiabilityGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </EscrowAccountLiabilityGrp>
      <LoansFromOfficersDirectorsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </LoansFromOfficersDirectorsGrp>
      <MortgNotesPyblScrdInvstPropGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </MortgNotesPyblScrdInvstPropGrp>
      <UnsecuredNotesLoansPayableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </UnsecuredNotesLoansPayableGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>59717916</BOYAmt>
        <EOYAmt>62957218</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>98403421</BOYAmt>
        <EOYAmt>84243927</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>49232724</BOYAmt>
        <EOYAmt>45429937</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <CapStkTrPrinCurrentFundsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </CapStkTrPrinCurrentFundsGrp>
      <PdInCapSrplsLandBldgEqpFundGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </PdInCapSrplsLandBldgEqpFundGrp>
      <RtnEarnEndowmentIncmOthFndsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </RtnEarnEndowmentIncmOthFndsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>147636145</BOYAmt>
        <EOYAmt>129673864</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>207354061</BOYAmt>
        <EOYAmt>192631082</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <InfoInScheduleOPartXIInd>X</InfoInScheduleOPartXIInd>
      <ReconcilationRevenueExpnssAmt>-9466164</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>-11884802</NetUnrlzdGainsLossesInvstAmt>
      <DonatedServicesAndUseFcltsAmt>-63954</DonatedServicesAndUseFcltsAmt>
      <InvestmentExpenseAmt>-316359</InvestmentExpenseAmt>
      <PriorPeriodAdjustmentsAmt>0</PriorPeriodAdjustmentsAmt>
      <OtherChangesInNetAssetsAmt>1068998</OtherChangesInNetAssetsAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>false</AccountantCompileOrReviewInd>
      <FSAuditedInd>true</FSAuditedInd>
      <FSAuditedBasisGrp>
        <ConsolidatedBasisFinclStmtInd>X</ConsolidatedBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>true</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>false</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="IRS990ScheduleA" softwareId="22016089" softwareVersionNum="2022v5.0">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>63291987</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>59972314</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>50983746</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>99456148</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>111805407</CurrentTaxYearAmt>
        <TotalAmt>385509602</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TaxRevLeviedOrgnztnlBnft170Grp>
        <TotalAmt>0</TotalAmt>
      </TaxRevLeviedOrgnztnlBnft170Grp>
      <GovtFurnSrvcFcltsVl170Grp>
        <TotalAmt>0</TotalAmt>
      </GovtFurnSrvcFcltsVl170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>63291987</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>59972314</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>50983746</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>99456148</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>111805407</CurrentTaxYearAmt>
        <TotalAmt>385509602</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>19028970</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>366480632</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>5221701</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>4928838</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>1217543</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>1156360</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>1438781</CurrentTaxYearAmt>
        <TotalAmt>13963223</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <UnrelatedBusinessNetIncm170Grp>
        <TotalAmt>0</TotalAmt>
      </UnrelatedBusinessNetIncm170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>34200</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>86442</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>15070</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>3574</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>26758</CurrentTaxYearAmt>
        <TotalAmt>166044</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>399638869</TotalSupportAmt>
      <GrossReceiptsRltdActivitiesAmt>65072779</GrossReceiptsRltdActivitiesAmt>
      <PublicSupportCY170Pct>0.9170</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.8199</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
      <Form990ScheduleAPartVIGrp>
        <FormAndLineReferenceDesc>Schedule A, Part II, Line 10 Other Income</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION - OTHER INCOME, COLUMN A - 34200.0, COLUMN B - 86442.0, COLUMN C - 15070.0, COLUMN D - 3574.0, COLUMN E - 26758.0, COLUMN F - 166044.0;</ExplanationTxt>
      </Form990ScheduleAPartVIGrp>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="IRS990ScheduleB" softwareId="22016089" softwareVersionNum="2022v5.0">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleC documentId="IRS990ScheduleC" softwareId="22016089" softwareVersionNum="2022v5.0">
      <TotalGrassrootsLobbyingGrp>
        <FilingOrganizationsTotalAmt>15803</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>15803</AffiliatedGroupTotalAmt>
      </TotalGrassrootsLobbyingGrp>
      <TotalDirectLobbyingGrp>
        <FilingOrganizationsTotalAmt>277717</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>277717</AffiliatedGroupTotalAmt>
      </TotalDirectLobbyingGrp>
      <TotalLobbyingExpendGrp>
        <FilingOrganizationsTotalAmt>293520</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>293520</AffiliatedGroupTotalAmt>
      </TotalLobbyingExpendGrp>
      <OtherExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>103643020</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>103669862</AffiliatedGroupTotalAmt>
      </OtherExemptPurposeExpendGrp>
      <TotalExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>103936540</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>103963382</AffiliatedGroupTotalAmt>
      </TotalExemptPurposeExpendGrp>
      <LobbyingNontaxableAmountGrp>
        <FilingOrganizationsTotalAmt>1000000</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>1000000</AffiliatedGroupTotalAmt>
      </LobbyingNontaxableAmountGrp>
      <GrassrootsNontaxableGrp>
        <FilingOrganizationsTotalAmt>250000</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>250000</AffiliatedGroupTotalAmt>
      </GrassrootsNontaxableGrp>
      <TotLbbyngGrassrootMnsNonTxGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>0</AffiliatedGroupTotalAmt>
      </TotLbbyngGrassrootMnsNonTxGrp>
      <TotLbbyExpendMnsLbbyngNonTxGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>0</AffiliatedGroupTotalAmt>
      </TotLbbyExpendMnsLbbyngNonTxGrp>
      <AvgLobbyingNontaxableAmountGrp>
        <CurrentYearMinus3Amt>1000000</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>1000000</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>1000000</CurrentYearMinus1Amt>
        <CurrentYearAmt>1000000</CurrentYearAmt>
        <TotalAmt>4000000</TotalAmt>
      </AvgLobbyingNontaxableAmountGrp>
      <LobbyingCeilingAmt>6000000</LobbyingCeilingAmt>
      <AvgTotalLobbyingExpendGrp>
        <CurrentYearMinus3Amt>343462</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>172474</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>204997</CurrentYearMinus1Amt>
        <CurrentYearAmt>293520</CurrentYearAmt>
        <TotalAmt>1014453</TotalAmt>
      </AvgTotalLobbyingExpendGrp>
      <AvgGrassrootsNontaxableGrp>
        <CurrentYearMinus3Amt>250000</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>250000</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>250000</CurrentYearMinus1Amt>
        <CurrentYearAmt>250000</CurrentYearAmt>
        <TotalAmt>1000000</TotalAmt>
      </AvgGrassrootsNontaxableGrp>
      <GrassrootsCeilingAmt>1500000</GrassrootsCeilingAmt>
      <AvgGrassrootsLobbyingExpendGrp>
        <CurrentYearMinus3Amt>86368</CurrentYearMinus3Amt>
        <CurrentYearMinus2Amt>386160</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>26906</CurrentYearMinus1Amt>
        <CurrentYearAmt>15803</CurrentYearAmt>
        <TotalAmt>515237</TotalAmt>
      </AvgGrassrootsLobbyingExpendGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule C, Part II-A Lobbying Expenses</FormAndLineReferenceDesc>
        <ExplanationTxt>PUBLIC POLICY AND ADVOCACY INITIATIVES HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE IMPORTANCE OF THIS WORK TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED LOBBYING ACTIVITIES TO ACHIEVE LEGISLATIVE AND REGULATORY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE AND FUND CRITICAL BREAST CANCER RESEARCH.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleC>
    <IRS990ScheduleD documentId="IRS990ScheduleD" softwareId="22016089" softwareVersionNum="2022v5.0">
      <CYEndwmtFundGrp>
        <BeginningYearBalanceAmt>1346868</BeginningYearBalanceAmt>
        <ContributionsAmt>2279000</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>-7607</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>5713</OtherExpendituresAmt>
        <EndYearBalanceAmt>3612548</EndYearBalanceAmt>
      </CYEndwmtFundGrp>
      <CYMinus1YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1342173</BeginningYearBalanceAmt>
        <ContributionsAmt>0</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>10613</InvestmentEarningsOrLossesAmt>
        <GrantsOrScholarshipsAmt>0</GrantsOrScholarshipsAmt>
        <OtherExpendituresAmt>5918</OtherExpendituresAmt>
        <AdministrativeExpensesAmt>0</AdministrativeExpensesAmt>
        <EndYearBalanceAmt>1346868</EndYearBalanceAmt>
      </CYMinus1YrEndwmtFundGrp>
      <CYMinus2YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1337562</BeginningYearBalanceAmt>
        <ContributionsAmt>0</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>10279</InvestmentEarningsOrLossesAmt>
        <GrantsOrScholarshipsAmt>0</GrantsOrScholarshipsAmt>
        <OtherExpendituresAmt>5668</OtherExpendituresAmt>
        <AdministrativeExpensesAmt>0</AdministrativeExpensesAmt>
        <EndYearBalanceAmt>1342173</EndYearBalanceAmt>
      </CYMinus2YrEndwmtFundGrp>
      <CYMinus3YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1333603</BeginningYearBalanceAmt>
        <ContributionsAmt>0</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>9803</InvestmentEarningsOrLossesAmt>
        <GrantsOrScholarshipsAmt>0</GrantsOrScholarshipsAmt>
        <OtherExpendituresAmt>5844</OtherExpendituresAmt>
        <AdministrativeExpensesAmt>0</AdministrativeExpensesAmt>
        <EndYearBalanceAmt>1337562</EndYearBalanceAmt>
      </CYMinus3YrEndwmtFundGrp>
      <CYMinus4YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>1362090</BeginningYearBalanceAmt>
        <ContributionsAmt>0</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>-4016</InvestmentEarningsOrLossesAmt>
        <GrantsOrScholarshipsAmt>0</GrantsOrScholarshipsAmt>
        <OtherExpendituresAmt>24267</OtherExpendituresAmt>
        <AdministrativeExpensesAmt>204</AdministrativeExpensesAmt>
        <EndYearBalanceAmt>1333603</EndYearBalanceAmt>
      </CYMinus4YrEndwmtFundGrp>
      <BoardDesignatedBalanceEOYPct>0.277</BoardDesignatedBalanceEOYPct>
      <PrmnntEndowmentBalanceEOYPct>0.721</PrmnntEndowmentBalanceEOYPct>
      <TermEndowmentBalanceEOYPct>0.002</TermEndowmentBalanceEOYPct>
      <EndowmentsHeldUnrelatedOrgInd>false</EndowmentsHeldUnrelatedOrgInd>
      <EndowmentsHeldRelatedOrgInd>false</EndowmentsHeldRelatedOrgInd>
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>2357161</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>1967638</DepreciationAmt>
        <BookValueAmt>389523</BookValueAmt>
      </EquipmentGrp>
      <OtherLandBuildingsGrp>
        <OtherCostOrOtherBasisAmt>11575780</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>7611768</DepreciationAmt>
        <BookValueAmt>3964012</BookValueAmt>
      </OtherLandBuildingsGrp>
      <TotalBookValueLandBuildingsAmt>4353535</TotalBookValueLandBuildingsAmt>
      <OtherSecuritiesGrp>
        <Desc>PRIVATE EQUITY FUND</Desc>
        <BookValueAmt>43470000</BookValueAmt>
        <MethodValuationCd>F</MethodValuationCd>
      </OtherSecuritiesGrp>
      <TotalBookValueSecuritiesAmt>43470000</TotalBookValueSecuritiesAmt>
      <TotalLiabilityAmt>0</TotalLiabilityAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>127818234</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>-11884802</NetUnrealizedGainsInvstAmt>
      <DonatedServicesAndUseFcltsAmt>32764307</DonatedServicesAndUseFcltsAmt>
      <OtherRevenueAmt>-342617</OtherRevenueAmt>
      <RevenueNotReportedAmt>20536888</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>107281346</RevenueSubtotalAmt>
      <InvestmentExpensesNotIncldAmt>316359</InvestmentExpensesNotIncldAmt>
      <OtherRevenuesNotIncludedAmt>0</OtherRevenuesNotIncludedAmt>
      <RevenueNotReportedFinclStmtAmt>316359</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>107597705</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>148480516</TotExpnsEtcAuditedFinclStmtAmt>
      <DonatedServicesUseFcltsAmt>32485644</DonatedServicesUseFcltsAmt>
      <OtherExpensesIncludedAmt>-1068997</OtherExpensesIncludedAmt>
      <ExpensesNotReportedAmt>31416647</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>117063869</ExpensesSubtotalAmt>
      <OtherExpensesNotIncludedAmt>0</OtherExpensesNotIncludedAmt>
      <ExpensesNotRptFinclStmtAmt>0</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>117063869</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule D, Part V, Line 4 Intended uses of endowment funds</FormAndLineReferenceDesc>
        <ExplanationTxt>KOMEN HAS FIVE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, TWO GENERAL ENDOWMENTS, AND A PERPETUAL TRUST. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, THE GENERAL ENDOWMENT AND PERPETUAL TRUST'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2023</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990</FormAndLineReferenceDesc>
        <ExplanationTxt>In Kind Services Direct Costs - -342617</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990</FormAndLineReferenceDesc>
        <ExplanationTxt>Rescinded Grants - -1101560 Program Cost of Goods Sold - 32563</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="IRS990ScheduleF" softwareId="22016089" softwareVersionNum="2022v5.0">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Research</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>31483</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Fundraising</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Fundraising Support</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>21940</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>4</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Research</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>238914</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Learning Mgmt System</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>15007</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Mission Tool Development</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>30375</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Professional Membership</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>3250</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>3</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Research</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>295386</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Mission Support</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>68946</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Mission Tool Development</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>33308</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Professional Membership</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>18000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Software Licenses</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>24261</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Research</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>1000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Public Relations</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Public Relations</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>8141</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Program Services</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Sponsorship of Mission Programs</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>102500</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>19</SubtotalEmployeesCnt>
      <ContinuationTotalOfficeCnt>0</ContinuationTotalOfficeCnt>
      <ContinuationTotalEmployeeCnt>0</ContinuationTotalEmployeeCnt>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>19</TotalEmployeeCnt>
      <SubtotalSpentAmt>892511</SubtotalSpentAmt>
      <ContinuationSpentAmt>0</ContinuationSpentAmt>
      <TotalSpentAmt>892511</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
        <CashGrantAmt>31483</CashGrantAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
        <CashGrantAmt>74544</CashGrantAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
        <CashGrantAmt>74544</CashGrantAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
        <CashGrantAmt>89827</CashGrantAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>North America (Canada &amp; Mexico only)</RegionTxt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
        <CashGrantAmt>145385</CashGrantAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
        <CashGrantAmt>75000</CashGrantAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
        <CashGrantAmt>75000</CashGrantAmt>
      </GrantsToOrgOutsideUSGrp>
      <Total501c3OrgCnt>5</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <TransferToForeignCorpInd>true</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>false</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>true</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>false</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>false</ForeignPartnershipInd>
      <BoycottCountriesInd>false</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds</FormAndLineReferenceDesc>
        <ExplanationTxt>AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT SCIENTIFIC PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, Part IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements</FormAndLineReferenceDesc>
        <ExplanationTxt>EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA &amp; MEXICO ONLY)-Accrual</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements</FormAndLineReferenceDesc>
        <ExplanationTxt>EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA &amp; MEXICO ONLY)-Accrual</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleG documentId="IRS990ScheduleG" softwareId="22016089" softwareVersionNum="2022v5.0">
      <MailSolicitationsInd>X</MailSolicitationsInd>
      <EmailSolicitationsInd>X</EmailSolicitationsInd>
      <PhoneSolicitationsInd>X</PhoneSolicitationsInd>
      <InPersonSolicitationsInd>X</InPersonSolicitationsInd>
      <SolicitationOfNonGovtGrantsInd>X</SolicitationOfNonGovtGrantsInd>
      <SpecialFundraisingEventsInd>X</SpecialFundraisingEventsInd>
      <AgrmtProfFundraisingActyInd>true</AgrmtProfFundraisingActyInd>
      <FundraiserActivityInfoGrp>
        <OrganizationBusinessName>
          <BusinessNameLine1Txt>Event 360</BusinessNameLine1Txt>
        </OrganizationBusinessName>
        <USAddress>
          <AddressLine1Txt>55 E Jackson Blvd Suite 1010</AddressLine1Txt>
          <CityNm>Chicago</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60604</ZIPCd>
        </USAddress>
        <ActivityTxt>Fundraising Consultant</ActivityTxt>
        <FundraiserControlOfFundsInd>false</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>14471684</GrossReceiptsAmt>
        <RetainedByContractorAmt>783234</RetainedByContractorAmt>
        <NetToOrganizationAmt>13688450</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <FundraiserActivityInfoGrp>
        <OrganizationBusinessName>
          <BusinessNameLine1Txt>Revunami Inc</BusinessNameLine1Txt>
        </OrganizationBusinessName>
        <USAddress>
          <AddressLine1Txt>228 E 85th St Suite 9C</AddressLine1Txt>
          <CityNm>New York</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10028</ZIPCd>
        </USAddress>
        <ActivityTxt>Marketing Consultant</ActivityTxt>
        <FundraiserControlOfFundsInd>false</FundraiserControlOfFundsInd>
        <RetainedByContractorAmt>14061</RetainedByContractorAmt>
        <NetToOrganizationAmt>-14061</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <FundraiserActivityInfoGrp>
        <OrganizationBusinessName>
          <BusinessNameLine1Txt>RKD Group LLC</BusinessNameLine1Txt>
        </OrganizationBusinessName>
        <USAddress>
          <AddressLine1Txt>3400 Waterview Parkway Suite 250</AddressLine1Txt>
          <CityNm>Richardson</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>75080</ZIPCd>
        </USAddress>
        <ActivityTxt>Fundraising Consultant</ActivityTxt>
        <FundraiserControlOfFundsInd>false</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>24004781</GrossReceiptsAmt>
        <RetainedByContractorAmt>533010</RetainedByContractorAmt>
        <NetToOrganizationAmt>23471771</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <FundraiserActivityInfoGrp>
        <OrganizationBusinessName>
          <BusinessNameLine1Txt>InKind Inc DBA GoodUnited</BusinessNameLine1Txt>
        </OrganizationBusinessName>
        <USAddress>
          <AddressLine1Txt>796 Meeting STreet</AddressLine1Txt>
          <CityNm>Charleston</CityNm>
          <StateAbbreviationCd>SC</StateAbbreviationCd>
          <ZIPCd>29403</ZIPCd>
        </USAddress>
        <ActivityTxt>Fundraising Consulting</ActivityTxt>
        <FundraiserControlOfFundsInd>false</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>1484191</GrossReceiptsAmt>
        <RetainedByContractorAmt>33423</RetainedByContractorAmt>
        <NetToOrganizationAmt>1450768</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <TotalGrossReceiptsAmt>39960656</TotalGrossReceiptsAmt>
      <TotalRetainedByContractorsAmt>1363728</TotalRetainedByContractorsAmt>
      <TotalNetToOrganizationAmt>38596928</TotalNetToOrganizationAmt>
      <LicensedStatesCd>CA</LicensedStatesCd>
      <LicensedStatesCd>CO</LicensedStatesCd>
      <LicensedStatesCd>CT</LicensedStatesCd>
      <LicensedStatesCd>DC</LicensedStatesCd>
      <LicensedStatesCd>FL</LicensedStatesCd>
      <LicensedStatesCd>GA</LicensedStatesCd>
      <LicensedStatesCd>AL</LicensedStatesCd>
      <LicensedStatesCd>HI</LicensedStatesCd>
      <LicensedStatesCd>ID</LicensedStatesCd>
      <LicensedStatesCd>IL</LicensedStatesCd>
      <LicensedStatesCd>IN</LicensedStatesCd>
      <LicensedStatesCd>IA</LicensedStatesCd>
      <LicensedStatesCd>KS</LicensedStatesCd>
      <LicensedStatesCd>KY</LicensedStatesCd>
      <LicensedStatesCd>LA</LicensedStatesCd>
      <LicensedStatesCd>ME</LicensedStatesCd>
      <LicensedStatesCd>AK</LicensedStatesCd>
      <LicensedStatesCd>MD</LicensedStatesCd>
      <LicensedStatesCd>MA</LicensedStatesCd>
      <LicensedStatesCd>MI</LicensedStatesCd>
      <LicensedStatesCd>MN</LicensedStatesCd>
      <LicensedStatesCd>MS</LicensedStatesCd>
      <LicensedStatesCd>MO</LicensedStatesCd>
      <LicensedStatesCd>MT</LicensedStatesCd>
      <LicensedStatesCd>NE</LicensedStatesCd>
      <LicensedStatesCd>NV</LicensedStatesCd>
      <LicensedStatesCd>NH</LicensedStatesCd>
      <LicensedStatesCd>NJ</LicensedStatesCd>
      <LicensedStatesCd>NM</LicensedStatesCd>
      <LicensedStatesCd>NY</LicensedStatesCd>
      <LicensedStatesCd>NC</LicensedStatesCd>
      <LicensedStatesCd>ND</LicensedStatesCd>
      <LicensedStatesCd>OH</LicensedStatesCd>
      <LicensedStatesCd>OK</LicensedStatesCd>
      <LicensedStatesCd>OR</LicensedStatesCd>
      <LicensedStatesCd>PA</LicensedStatesCd>
      <LicensedStatesCd>AZ</LicensedStatesCd>
      <LicensedStatesCd>RI</LicensedStatesCd>
      <LicensedStatesCd>SC</LicensedStatesCd>
      <LicensedStatesCd>SD</LicensedStatesCd>
      <LicensedStatesCd>TN</LicensedStatesCd>
      <LicensedStatesCd>TX</LicensedStatesCd>
      <LicensedStatesCd>UT</LicensedStatesCd>
      <LicensedStatesCd>VT</LicensedStatesCd>
      <LicensedStatesCd>VA</LicensedStatesCd>
      <LicensedStatesCd>AR</LicensedStatesCd>
      <LicensedStatesCd>WA</LicensedStatesCd>
      <LicensedStatesCd>WV</LicensedStatesCd>
      <LicensedStatesCd>WI</LicensedStatesCd>
      <LicensedStatesCd>WY</LicensedStatesCd>
      <FundraisingEventInformationGrp>
        <Event1Nm>3 Day Series</Event1Nm>
        <GrossReceiptsEvent1Amt>14385465</GrossReceiptsEvent1Amt>
        <CharitableContriEvent1Amt>14171508</CharitableContriEvent1Amt>
        <GrossRevenueEvent1Amt>213957</GrossRevenueEvent1Amt>
        <CashPrizesEvent1Amt>0</CashPrizesEvent1Amt>
        <NonCashPrizesEvent1Amt>15601</NonCashPrizesEvent1Amt>
        <RentFacilityCostsEvent1Amt>2020744</RentFacilityCostsEvent1Amt>
        <FoodAndBeverageEvent1Amt>475001</FoodAndBeverageEvent1Amt>
        <EntertainmentEvent1Amt>0</EntertainmentEvent1Amt>
        <OtherDirectExpensesEvent1Amt>1351776</OtherDirectExpensesEvent1Amt>
        <Event2Nm>Race-Walk Events</Event2Nm>
        <GrossReceiptsEvent2Amt>20377979</GrossReceiptsEvent2Amt>
        <CharitableContriEvent2Amt>19569955</CharitableContriEvent2Amt>
        <GrossRevenueEvent2Amt>808024</GrossRevenueEvent2Amt>
        <CashPrizesEvent2Amt>0</CashPrizesEvent2Amt>
        <NonCashPrizesEvent2Amt>731448</NonCashPrizesEvent2Amt>
        <RentFacilityCostsEvent2Amt>263961</RentFacilityCostsEvent2Amt>
        <FoodAndBeverageEvent2Amt>264485</FoodAndBeverageEvent2Amt>
        <EntertainmentEvent2Amt>18952</EntertainmentEvent2Amt>
        <OtherDirectExpensesEvent2Amt>2643606</OtherDirectExpensesEvent2Amt>
        <OtherEventsTotalCnt>50</OtherEventsTotalCnt>
        <GrossReceiptsOtherEventsAmt>2725124</GrossReceiptsOtherEventsAmt>
        <CharitableContriOtherEventsAmt>1926871</CharitableContriOtherEventsAmt>
        <GrossRevenueOtherEventsAmt>798253</GrossRevenueOtherEventsAmt>
        <CashPrizesOtherEventsAmt>0</CashPrizesOtherEventsAmt>
        <NonCashPrizesOtherEventsAmt>21957</NonCashPrizesOtherEventsAmt>
        <RentFcltyCostsOtherEventsAmt>190649</RentFcltyCostsOtherEventsAmt>
        <FoodAndBeverageOtherEventsAmt>325855</FoodAndBeverageOtherEventsAmt>
        <EntertainmentOtherEventsAmt>26300</EntertainmentOtherEventsAmt>
        <OthDirectExpnssOtherEventsAmt>183539</OthDirectExpnssOtherEventsAmt>
        <GrossReceiptsTotalAmt>37488568</GrossReceiptsTotalAmt>
        <CharitableContributionsTotAmt>35668334</CharitableContributionsTotAmt>
        <GrossRevenueTotalEventsAmt>1820234</GrossRevenueTotalEventsAmt>
        <CashPrizesTotalEventsAmt>0</CashPrizesTotalEventsAmt>
        <NonCashPrizesTotalEventsAmt>769006</NonCashPrizesTotalEventsAmt>
        <RentFcltyCostsTotalEventsAmt>2475354</RentFcltyCostsTotalEventsAmt>
        <FoodAndBeverageTotalEventsAmt>1065341</FoodAndBeverageTotalEventsAmt>
        <EntertainmentTotalEventsAmt>45252</EntertainmentTotalEventsAmt>
        <OthDirectExpnssTotalEventsAmt>4178921</OthDirectExpnssTotalEventsAmt>
        <DirectExpenseSummaryEventsAmt>8533874</DirectExpenseSummaryEventsAmt>
        <NetIncomeSummaryAmt>-6713640</NetIncomeSummaryAmt>
      </FundraisingEventInformationGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule G, Part II Net Income Summary</FormAndLineReferenceDesc>
        <ExplanationTxt>Gross receipts are reduced by the amount of fundraising contributions, per IRS instructions. The contributions for fiscal year 2023 were $35,668,334.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleG>
    <IRS990ScheduleI documentId="IRS990ScheduleI" softwareId="22016089" softwareVersionNum="2022v5.0">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Alliance for Clinical Trials in Oncology</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>020464400</RecipientEIN>
        <CashGrantAmt>103344</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>AMITA Health</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>362235165</RecipientEIN>
        <CashGrantAmt>12600</CashGrantAmt>
        <PurposeOfGrantTxt>Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Barnes-Jewish Hospital</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>237309937</RecipientEIN>
        <CashGrantAmt>37500</CashGrantAmt>
        <PurposeOfGrantTxt>Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Baylor College Medicine</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>741613878</RecipientEIN>
        <CashGrantAmt>347799</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Baylor University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>741159753</RecipientEIN>
        <CashGrantAmt>330000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Board of Regents of the University of</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>731563627</RecipientEIN>
        <CashGrantAmt>57504</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Boston University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>042103547</RecipientEIN>
        <CashGrantAmt>199448</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Brigham and Women's Hospital</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>042312909</RecipientEIN>
        <CashGrantAmt>36000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Burnham Institute for Medical Research</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>510197108</RecipientEIN>
        <CashGrantAmt>49994</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Cedars Sinai Medical Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>951644600</RecipientEIN>
        <CashGrantAmt>115337</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Columbia University Medical Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>135598093</RecipientEIN>
        <CashGrantAmt>386422</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Dana Farber Cancer Institute</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>042263040</RecipientEIN>
        <CashGrantAmt>892588</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Dana-Farber Cancer Institute Inc</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>042263040</RecipientEIN>
        <CashGrantAmt>392380</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Duke University Medical Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>560532129</RecipientEIN>
        <CashGrantAmt>546914</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Eastern Michigan University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>382953297</RecipientEIN>
        <CashGrantAmt>87500</CashGrantAmt>
        <PurposeOfGrantTxt>Education</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ECOG Research and Education Foundation</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>391723095</RecipientEIN>
        <CashGrantAmt>101486</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Emory University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>580566256</RecipientEIN>
        <CashGrantAmt>189917</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Georgetown University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>522339873</RecipientEIN>
        <CashGrantAmt>5815</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Harvard Medical School</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>042103580</RecipientEIN>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Indiana University (Indianapolis)</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>356001673</RecipientEIN>
        <CashGrantAmt>809308</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Johns Hopkins University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>520595110</RecipientEIN>
        <CashGrantAmt>312500</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Johns Hopkins University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>520595110</RecipientEIN>
        <CashGrantAmt>75000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Lake County Health Department</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>593502843</RecipientEIN>
        <CashGrantAmt>5105</CashGrantAmt>
        <PurposeOfGrantTxt>Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Leland Stanford Jr University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>941156365</RecipientEIN>
        <CashGrantAmt>300000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Loyola University Chicago</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>361408475</RecipientEIN>
        <CashGrantAmt>165000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Mayo Clinic Jacksonville</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>593337028</RecipientEIN>
        <CashGrantAmt>220000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>McDonough County Health Department</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>376001537</RecipientEIN>
        <CashGrantAmt>4419</CashGrantAmt>
        <PurposeOfGrantTxt>Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Memorial Sloan-Kettering Cancer Ctr</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>131924236</RecipientEIN>
        <CashGrantAmt>374999</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Mount Sinai School of Medicine</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>136171197</RecipientEIN>
        <CashGrantAmt>134750</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Oregon Health &amp; Science University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>752668014</RecipientEIN>
        <CashGrantAmt>429396</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Parkland Foundation</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>752089180</RecipientEIN>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Presence Hospitals PRV</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>344195126</RecipientEIN>
        <CashGrantAmt>6300</CashGrantAmt>
        <PurposeOfGrantTxt>Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Princeton University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>210634501</RecipientEIN>
        <CashGrantAmt>300000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Roswell Park Alliance Foundation</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>161391608</RecipientEIN>
        <CashGrantAmt>75000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Rush University Medical Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>362174823</RecipientEIN>
        <CashGrantAmt>220000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Stanford University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>941156365</RecipientEIN>
        <CashGrantAmt>375137</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>SUNY at Stony Brook</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>141368361</RecipientEIN>
        <CashGrantAmt>33783</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>The Ohio State University College</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>316025986</RecipientEIN>
        <CashGrantAmt>67500</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>The Salk Institute</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>952160097</RecipientEIN>
        <CashGrantAmt>75000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>The University of Chicago</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>362177139</RecipientEIN>
        <CashGrantAmt>67500</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>The University of Toledo</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>346401483</RecipientEIN>
        <CashGrantAmt>57190</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Touchette Regional Hospital Inc</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>371305510</RecipientEIN>
        <CashGrantAmt>37500</CashGrantAmt>
        <PurposeOfGrantTxt>Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Univ of North Carolina at Chapel Hill</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>566001393</RecipientEIN>
        <CashGrantAmt>652667</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Univ of Texas MD Anderson Cancer Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>746001118</RecipientEIN>
        <CashGrantAmt>731645</CashGrantAmt>
        <PurposeOfGrantTxt>Research, Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of California at San Francis</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>946036493</RecipientEIN>
        <CashGrantAmt>283458</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of California-Davis</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>946036494</RecipientEIN>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Chicago</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>362177139</RecipientEIN>
        <CashGrantAmt>200000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Kansas Center for Research</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>480680117</RecipientEIN>
        <CashGrantAmt>59518</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Kentucky Research Fndn</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>616033693</RecipientEIN>
        <CashGrantAmt>224933</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Michigan</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>386006309</RecipientEIN>
        <CashGrantAmt>180000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of North Carolina</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>566001393</RecipientEIN>
        <CashGrantAmt>220000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Pennsylvania</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>231352685</RecipientEIN>
        <CashGrantAmt>571450</CashGrantAmt>
        <PurposeOfGrantTxt>Research, Patient Care</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Pittsburgh</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>250966691</RecipientEIN>
        <CashGrantAmt>29958</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Pittsburgh</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>250965591</RecipientEIN>
        <CashGrantAmt>135319</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Texas at Health Science Ctr</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>741587488</RecipientEIN>
        <CashGrantAmt>53764</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Utah</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>876000525</RecipientEIN>
        <CashGrantAmt>292180</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UT HSC - San Antonio</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>741586031</RecipientEIN>
        <CashGrantAmt>393124</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UT Southwestern Medical Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>746000203</RecipientEIN>
        <CashGrantAmt>150000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Vanderbilt University Medical Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>620476822</RecipientEIN>
        <CashGrantAmt>486465</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Virginia Commonwealth University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>546001758</RecipientEIN>
        <CashGrantAmt>240000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Wake Forest University Health Sciences</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>223849199</RecipientEIN>
        <CashGrantAmt>59926</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Washington University at St Louis</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>430653611</RecipientEIN>
        <CashGrantAmt>131984</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Wayne State University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>366028429</RecipientEIN>
        <CashGrantAmt>33240</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Weill Medical College of Cornell Univ</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>131623978</RecipientEIN>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Yale University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <RecipientEIN>030179440</RecipientEIN>
        <CashGrantAmt>307788</CashGrantAmt>
        <PurposeOfGrantTxt>Research</PurposeOfGrantTxt>
      </RecipientTable>
      <Total501c3OrgCnt>61</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <GrantsOtherAsstToIndivInUSGrp>
        <GrantTypeTxt>Patient Care Assistance @ $500</GrantTypeTxt>
        <RecipientCnt>11994</RecipientCnt>
        <CashGrantAmt>3081750</CashGrantAmt>
      </GrantsOtherAsstToIndivInUSGrp>
      <GrantsOtherAsstToIndivInUSGrp>
        <GrantTypeTxt>Patient Care Assistance @ $750</GrantTypeTxt>
        <RecipientCnt>4109</RecipientCnt>
        <CashGrantAmt>5997000</CashGrantAmt>
      </GrantsOtherAsstToIndivInUSGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds.</FormAndLineReferenceDesc>
        <ExplanationTxt>SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR COMMUNITY HEALTH AND EDUCATION GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="IRS990ScheduleJ" softwareId="22016089" softwareVersionNum="2022v5.0">
      <CompensationCommitteeInd>X</CompensationCommitteeInd>
      <IndependentConsultantInd>X</IndependentConsultantInd>
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <WrittenEmploymentContractInd>X</WrittenEmploymentContractInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>false</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>false</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>false</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>false</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>false</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>false</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>false</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>false</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>false</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Dana Brown</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>Chief Operating Officer (Term 3/31/22)</TitleTxt>
        <BaseCompensationFilingOrgAmt>136744</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>46800</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1213</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>4200</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>1380</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>190337</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Eunice Nakamura</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>General Counsel and Corporate Secretary</TitleTxt>
        <BaseCompensationFilingOrgAmt>244099</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>28200</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1579</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>16754</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>6933</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>297565</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Paula Schneider</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>President and CEO</TitleTxt>
        <BaseCompensationFilingOrgAmt>631275</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>252285</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>4604</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>20057</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>7558</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>915779</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Ria Williams</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>Chief Fin &amp; Ops Officer</TitleTxt>
        <BaseCompensationFilingOrgAmt>282221</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>34800</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>2055</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>16874</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>13761</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>349711</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Lori Maris</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>SVP, OPS SERVICES &amp; SUPPORT</TitleTxt>
        <BaseCompensationFilingOrgAmt>212699</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>25800</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1734</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>8401</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>6948</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>255582</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Catherine Olivieri</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>SVP, Human Resources</TitleTxt>
        <BaseCompensationFilingOrgAmt>243713</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>30000</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>3362</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>14714</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>11705</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>303494</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Victoria Smart</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>SVP, Mission</TitleTxt>
        <BaseCompensationFilingOrgAmt>294149</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>34800</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>2528</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>13911</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>1794</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>347182</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Srinivasu Avadhanula</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, BI Platform &amp; Engineering</TitleTxt>
        <BaseCompensationFilingOrgAmt>223372</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>24960</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1460</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>12379</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>11235</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>273406</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Kari Bodell</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Development Programs Strategy</TitleTxt>
        <BaseCompensationFilingOrgAmt>213599</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>24600</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1426</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>12375</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>1794</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>253794</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Sarah Rosales</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Corporate Partnerships</TitleTxt>
        <BaseCompensationFilingOrgAmt>227827</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>28200</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1331</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>13683</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>15668</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>286709</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Catherine Stone</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Community Health</TitleTxt>
        <BaseCompensationFilingOrgAmt>189677</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>22000</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1383</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>11337</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>1794</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>226191</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <BusinessName>
          <BusinessNameLine1Txt>Michelle Strong</BusinessNameLine1Txt>
        </BusinessName>
        <TitleTxt>VP, Marketing Strategy</TitleTxt>
        <BaseCompensationFilingOrgAmt>207548</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>24000</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>1632</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>14372</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>7988</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>255540</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
    </IRS990ScheduleJ>
    <IRS990ScheduleM documentId="IRS990ScheduleM" softwareId="22016089" softwareVersionNum="2022v5.0">
      <FoodInventoryGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <ContributionCnt>56</ContributionCnt>
        <NoncashContributionsRptF990Amt>148547</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>Cost</MethodOfDeterminingRevenuesTxt>
      </FoodInventoryGrp>
      <OtherNonCashContriTableGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <Desc>Gift bags/Gift Cards</Desc>
        <ContributionCnt>53</ContributionCnt>
        <NoncashContributionsRptF990Amt>424435</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>Cost</MethodOfDeterminingRevenuesTxt>
      </OtherNonCashContriTableGrp>
      <OtherNonCashContriTableGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <Desc>Event Supplies</Desc>
        <ContributionCnt>7</ContributionCnt>
        <NoncashContributionsRptF990Amt>19495</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>Cost</MethodOfDeterminingRevenuesTxt>
      </OtherNonCashContriTableGrp>
      <Form8283ReceivedCnt>2</Form8283ReceivedCnt>
      <AnyPropertyThatMustBeHeldInd>false</AnyPropertyThatMustBeHeldInd>
      <ReviewProcessUnusualNCGiftsInd>false</ReviewProcessUnusualNCGiftsInd>
      <ThirdPartiesUsedInd>false</ThirdPartiesUsedInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule M, Part I Explanations of reporting method for number of contributions</FormAndLineReferenceDesc>
        <ExplanationTxt>Food inventory - Food &amp; Beverage Number of contributions Other - Gift bags/Gift Cards Number of contributions</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="IRS990ScheduleO" softwareId="22016089" softwareVersionNum="2022v5.0">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part I, Line 6 VOLUNTEERS</FormAndLineReferenceDesc>
        <ExplanationTxt>VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, THE SUSAN G. KOMEN 3 DAY SERIES, AND ADVOCACY PROGRAMS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part III, Line 4 Program service accomplishments</FormAndLineReferenceDesc>
        <ExplanationTxt>SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES FROM BREAST CANCER BY FINDING BREAKTHROUGHS TO PREVENT, DETECT, TREAT, AND CURE BREAST CANCER, AND BY MEETING THE MOST CRITICAL NEEDS IN COMMUNITIES TO ENSURE EVERYONE GETS THE BREAST CANCER CARE THEY NEED WHEN THEY NEED IT. KOMEN TAKES A 360 DEGREE APPROACH TO FIGHT BREAST CANCER THROUGH: - RESEARCH, TO DRIVE BREAKTHROUGHS THAT WILL BRING US NEW KNOWLEDGE AND ADVANCES IN CARE FOR ALL. -COMMUNITY HEALTH, TO EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION AND SUPPORT PEOPLE IN THEIR BREAST HEALTH JOURNEY THROUGH DIRECT SERVICES, COMMUNITY PROGRAMS AND HEALTH SYSTEMS CHANGE. - AND PUBLIC POLICY, WHERE WE ADVOCATE FOR POLICIES TO CREATE SYSTEMIC AND LASTING CHANGES THAT WILL FUND AND FACILITATE RESEARCH AND ALLEVIATE THE BURDEN ON PATIENTS AND PROTECT ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE OF THE U.S. GOVERNMENT WHILE PROVIDING REAL-TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS INVESTED OVER $1.1 BILLION IN BREAST CANCER RESEARCH IN MORE THAN 2800 GRANTS AND MORE THAN 500 CLINICAL TRIALS CONDUCTED BY THOUSANDS OF THE WORLD'S BEST AND BRIGHTEST RESEARCHERS ACROSS THE US AND AROUND THE WORLD. KOMEN HAS ALSO PROVIDED OVER $3.2 BILLION IN COMMUNITY INVESTMENT FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, ADVOCACY, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. WITH THIS INVESTMENT, KOMEN IS SUPPORTING LABORATORY RESEARCH, TRANSLATIONAL STUDIES, AND CLINICAL TRIALS THAT ARE PAVING THE ROAD WITH SCIENTIFIC DISCOVERIES THAT ARE: - UNRAVELLING THE BIOLOGY OF BREAST CANCER, - LEADING TO THE DEVELOPMENT OF NEW BREAST CANCER DRUGS, - DEVELOPMENT OF NEW TECHNOLOGIES AND TESTS, AND - NEW INTERVENTIONS THAT ARE CHANGING THE STANDARD OF BREAST CANCER CARE AND IMPROVING THE DELIVERY OF THAT CARE. OUR GOAL IS TO ADVANCE PERSONALIZED MEDICINE AND IMPROVE HEALTH OUTCOMES FOR EVERYONE. KOMEN HAS HAD MORE THAN 3,100 RESEARCH DISCOVERIES THAT ARE MOVING US CLOSER TO THAT GOAL. THIS INCLUDES OVER 700 NEW DISCOVERIES FOCUSED ON METASTATIC BREAST CANCER, MORE THAN 1,200 POTENTIAL TREATMENTS AND NEARLY 400 NEW STRATEGIES TO ELIMINATE BREAST CANCER DISPARITIES. THEY INCLUDE SUCH THINGS AS NEW BIOMARKERS, NEW DRUG TARGETS, NEW TREATMENTS, AND NEW HEALTH CARE DELIVERY TOOLS IN PAVING THIS ROAD WITH SCIENTIFIC DISCOVERIES, WE'RE ALSO PAVING IT WITH HOPE. THE HOPE THAT NEW WAYS TO DETECT, DIAGNOSE, TREAT, PREVENT AND, ULTIMATELY, CURE BREAST CANCER ARE AROUND THE CORNER AND THERE WHEN PEOPLE WITH BREAST CANCER NEED THEM TO ALLOW THEM TO LIVE LONGER, WITH IMPROVED QUALITY OF LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, AND DEVELOPING NEW APPROACHES TO ADDRESS DISPARITIES IN BREAST CANCER OUTCOMES, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS, TECHNOLOGIES AND INTERVENTIONS. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 54 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. THIS YEAR WE ANNOUNCED THE NEW CLASS OF NINE ESTEEMED BREAST CANCER RESEARCHERS AND TWO NEW PATIENT ADVOCATES TO THE KOMEN SCHOLARS. THESE INDIVIDUALS JOIN AN EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES WHO HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY23, KOMEN AWARDED 49 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, IN THE UNITED STATES, PUERTO RICO AND PORTUGAL. CAREER CATALYST RESEARCH GRANTS SUPPORT EARLY CAREER INVESTIGATORS CONDUCTING OUTSTANDING RESEARCH FOCUSED THE DEVELOPMENT OF NEXT GENERATION-TARGETED THERAPIES AND THE DEVELOPMENT OF INTERVENTIONS TO ELIMINATE BREAST CANCER HEALTH DISPARITIES. LEADERSHIP GRANTS SUPPORT KOMEN SCHOLARS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER AND ELIMINATING BREAST CANCER DISPARITIES. A SUPPLEMENT TO PROMOTE INCLUSION FOR RESEARCH EXCELLENCE (ASPIRE) GRANTS ARE SUPPLEMENT GRANTS TO AMPLIFY EXISTING FUNDING TO ENHANCE THE DIVERSITY OF THE BREAST CANCER RESEARCH WORKFORCE BY PROVIDING ESTABLISHED BREAST CANCER SCIENTISTS WITH SUPPLEMENTAL FUNDING TO SUPPORT RESEARCH TRAINEES FROM COMMUNITIES HISTORICALLY MINORITIZED AND MARGINALIZED IN RESEARCH. THE 49 RESEARCH GRANTS AWARDED IN FY23 ARE: CAREER CATALYST RESEARCH GRANTS: JULIA MCGUINNESS, M.D., FROM COLUMBIA UNIVERSITY, WILL DEVELOP A NEW MODEL TO ACCURATELY PREDICT BREAST CANCER RISK FROM SCREENING MAMMOGRAMS. SHE WILL UTILIZE SAMPLES FROM A RACIALLY/ETHNICALLY DIVERSE POPULATION IN NEW YORK CITY TO ENSURE THE MODEL REPRESENTS ALL BREAST CANCER PATIENTS. SHEARWOOD MCCLELLAND, M.D., FROM CASE WESTERN UNIVERSITY IS TESTING HOW PATIENT NAVIGATION IMPACTS ACCESS TO SHORT-COURSE RADIATION THERAPY (RT) FOR BLACK BREAST CANCER PATIENTS AND HOW FINANCIAL TOXICITIES INFLUENCE RT ADHERENCE. THE GOAL OF THIS RESEARCH IS TO DEMONSTRATE HOW PATIENT NAVIGATION AND SHORT-COURSE RT CAN ALLEVIATE FINANCIAL BURDEN AND HELP BLACK BREAST CANCER PATIENTS COMPLETE THEIR RT TREATMENTS. THIS WORK WILL ALSO CREATE A NEW EDUCATIONAL TOOL FOR PATIENT NAVIGATORS THAT EDUCATES ON THE USE OF SHORT-COURSE RT TO OVERCOME EXISTING BARRIERS TO CARE AND IMPROVE TREATMENT OUTCOMES. ANAND NARAYAN, M.D., PH.D., FROM THE UNIVERSITY OF WISCONSIN-MADISON, WILL CREATE A FREE ELECTRONIC HEALTH RECORDS PROGRAM THAT WILL IMPROVE HOW CLINICIANS MONITOR DELAYS IN MAMMOGRAMS, AND WILL ALSO QUANTIFY BARRIERS TO SCREENING AND CREATE PATIENT-CENTERED INTERVENTIONS THAT IMPROVE ACCESS TO BREAST IMAGING. THE GOAL IS TO IMPROVE TIMELY ACCESS TO MAMMOGRAMS TO CATCH MORE CANCERS EARLIER, PARTICULARLY IN MINORITY, RURAL AND UNINSURED POPULATIONS. BRUNO BARUFALDI, PH.D., FROM THE UNIVERSITY OF PENNSYLVANIA, WILL DEVELOP AN ARTIFICIAL INTELLIGENCE SYSTEM THAT INCORPORATES RACIALLY UNBIASED DESCRIPTORS OF BREAST COMPLEXITY AND SOCIOECONOMIC STATUS TO BETTER IDENTIFY INDIVIDUALS THAT NEED SUPPLEMENTAL BREAST SCREENING. THE GOAL OF THIS STUDY IS TO ENSURE ALL PATIENTS RECEIVE ACCESS TO THE SCREENING TESTS THEY NEED TO IDENTIFY BREAST CANCER EARLY. PRIYANKA VERMA, PH.D., FROM WASHINGTON UNIVERSITY IN ST. LOUIS, WILL AIM TO DEVELOP A NEW THERAPY FOR BRCA-MUTANT BREAST CANCERS THAT WILL TARGET AMPLIFIED IN LIVER CANCER 1 (ALC1), A PROTEIN THAT, WHEN INHIBITED, CAUSES DEATH OF BRCA-MUTANT BREAST CANCER CELLS WITH MINIMAL DAMAGE TO SURROUNDING HEALTHY CELLS. THE GOAL OF THIS STUDY IS TO PROVIDE AN INNOVATIVE AND PROMISING NEW THERAPY FOR HIGH-RISK WOMEN WITH BRCA MUTATIONS WHO CURRENTLY HAVE LIMITED TREATMENT OPTIONS. AIMILIA GASTOUNIOTI, PH.D., FROM WASHINGTON UNIVERSITY IN ST. LOUIS, WILL USE DIGITAL MAMMOGRAMS AND BREAST TOMOSYNTHESIS FROM BLACK WOMEN TO ENHANCE ARTIFICIAL INTELLIGENCE (AI) MODELS THAT BETTER PREDICT BREAST CANCER RISK FOR THIS GROUP, WHO HAVE BEEN HISTORICALLY OVERLOOKED IN PAST RISK ASSESSMENTS. THE GOAL OF THIS WORK IS TO DEVELOP CLINICALLY RELEVANT AI METHODS THAT DIFFERENTIATE BETWEEN HIGH- AND LOW-RISK INDIVIDUALS, AND ADVANCE BREAST CANCER RISK ASSESSMENTS AND PRECISION SCREENING RECOMMENDATIONS FOR BLACK WOMEN.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)</FormAndLineReferenceDesc>
        <ExplanationTxt>SARAH HILL, M.D., PH.D., FROM DANA- FARBER CANCER INSTITUTE, WILL INVESTIGATE THE ROLE OF A DNA DAMAGE REPAIR PROTEIN CALLED HBO1 IN TRIPLE NEGATIVE BREAST CANCER (TNBC). DR. HILL'S RESEARCH WILL DETERMINE IF HBO1 IS A PROMISING PHARMACEUTICAL TARGET FOR PATIENTS WITH TNBC, FOR WHOM TARGETED THERAPIES ARE URGENTLY NEEDED. LUCIA BORRIELLO, PH.D., FROM TEMPLE UNIVERSITY, WILL USE PRECLINICAL MODELS AND PATIENT DATA TO INVESTIGATE WHAT CAUSES BREAST TUMOR CELLS TO SPREAD AND LIE DORMANT BEFORE DEVELOPING INTO A DETECTABLE METASTATIC TUMOR. BY UNDERSTANDING THE CAUSES OF DORMANCY, DR. BORRIELLO HOPES THAT THERAPEUTIC STRATEGIES CAN BE DEVELOPED TO PREVENT DORMANT CELLS FROM DEVELOPING INTO METASTATIC BREAST CANCER. SHEHERYAR KABRAJI, BMBCH, OF ROSWELL PARK, WILL IDENTIFY MOLECULAR FEATURES ON TUMOR CELLS THAT CAUSE BLACK WOMEN WITH TRIPLE NEGATIVE BREAST CANCER (TNBC) TO RESPOND DIFFERENTLY TO NEOADJUVANT CHEMOTHERAPY THAN OTHER POPULATIONS, AND DETERMINE WHETHER THESE FEATURES COULD SERVE AS BIOMARKERS FOR THE DEVELOPMENT OF PERSONALIZED TNBC TREATMENTS. THIS RESEARCH COULD HELP REDUCE EXISTING DISPARITIES IN CHEMOTHERAPY BENEFITS AND ENSURE ALL TNBC PATIENTS HAVE EQUITABLE ACCESS TO THE BEST TREATMENTS POSSIBLE.NATHAN MERRILL, PH.D., FROM THE UNIVERSITY OF MICHIGAN, WILL EVALUATE A NOVEL DRUG COMBINATION THAT INCLUDES DNA DAMAGE RESPONSE (DDR) THERAPIES AND TREATMENTS THAT PREVENT TUMOR CELL GROWTH. USING PRECLINICAL MODELS AND CLINICAL MARKERS, THE GOAL OF THIS STUDY IS TO TARGET MARKERS OF SENSITIVITY AND RESISTANCE IN TRIPLE NEGATIVE BREAST CANCER (TNBC) TO HELP IDENTIFY DRUG COMBINATIONS THAT OFFER A PROMISING THERAPEUTIC STRATEGY FOR TNBC PATIENTS. GANG XIN, PH.D., FROM THE OHIO STATE UNIVERSITY, WILL INVESTIGATE HOW A POTENTIAL PROTEIN SWITCH COULD REGULATE TUMOR-ASSOCIATED MACROPHAGES (TAMS), A TYPE OF IMMUNE CELL, AND THE IMPACT ON THE RESPONSE OF BREAST TUMORS TO IMMUNOTHERAPY. THE GOAL OF THIS STUDY IS TO DEVELOP A TARGETED THERAPY THAT IMPROVES THE EFFICACY OF IMMUNOTHERAPY. ADRIENNE WAKS, M.D., FROM DANA FARBER CANCER INSTITUTE, WILL EXPLORE THE RELATIONSHIP BETWEEN ANTI-HER2 ANTIBODY THERAPY, ANTI-TUMOR IMMUNE RESPONSES AND CLINICAL OUTCOMES FOR PEOPLE WITH HER2+ BREAST CANCER. THE HOPE IS THAT THIS STUDY WILL IDENTIFY WHICH HER2+ PATIENTS WILL BENEFIT MOST FROM ANTI-HER2 THERAPIES AND GUIDE DEVELOPMENT OF NEW THERAPIES THAT WILL OVERCOME IMMUNE RESISTANCE FOR THESE PATIENTS. ERIKA CROSBY, PH.D., FROM DUKE UNIVERSITY, WILL USE A MOUSE MODEL TO INVESTIGATE HOW OBESITY IMPACTS RESPONSE TO IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER (TNBC), AND EVALUATE WHETHER THESE STUDY RESULTS CORRELATE WITH OBSERVATIONS FOR WOMEN PARTICIPATING IN THE CAROLINA BREAST CANCER STUDY. THIS RESEARCH WILL PROVIDE INSIGHT INTO THE PARADOX OF IMMUNOTHERAPY, OBESITY AND THEIR POTENTIAL EFFECTS IN TNBC. ISAAC CHAN, M.D., PH.D., FROM THE UNIVERSITY OF TEXAS SOUTHWESTERN, WILL CONDUCT A STUDY USING LYMPHOCYTES CALLED NATURAL KILLER CELLS THAT SUPPORT BREAST CANCER METASTASIS AND REPROGRAM THEM TO RETURN TO THEIR ORIGINAL TUMOR-FIGHTING ACTIVITY. THIS STUDY WILL HELP IDENTIFY PATIENTS WHO WOULD MOST BENEFIT FROM IMMUNOTHERAPIES, AS WELL AS INFLUENCE STRATEGIES FOR THE FUTURE DEVELOPMENT OF DRUGS THAT WILL MANIPULATE IMMUNE CELLS TO FIGHT METASTATIC TUMORS. ASPIRE GRANTS JULIE PALMER, SC.D., M.P.H., FROM BOSTON UNIVERSITY, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER ETIENNE X. HOLDER, PH.D., WHO WILL EXAMINE NEIGHBORHOOD-LEVEL PSYCHOSOCIAL FACTORS TO DETERMINE WHETHER CHRONIC PSYCHOSOCIAL DISTRESS LEADS TO THE ADVERSE BIOLOGICAL OUTCOMES THAT CONTRIBUTE TO THE DISPROPORTIONATELY HIGH BREAST CANCER MORTALITY EXPERIENCED BY BLACK WOMEN. THE GOAL OF THIS RESEARCH IS TO EXPLAIN THIS HIGH MORTALITY RATE AND DEVELOP INDIVIDUAL-LEVEL INTERVENTIONS SUCH AS MEDICATIONS AND MINDFULNESS TRAINING, AS WELL AS THE DEVELOPMENT OF NEW PROGRAMS AND POLICIES, TO COUNTERACT THE EFFECTS OF CHRONIC PSYCHOSOCIAL DISTRESS EXPERIENCED IN THESE COMMUNITIES. JENNIFER GUERRIERO, PH.D., FROM BRIGHAM AND WOMEN'S HOSPITAL, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER CARLOS WAGNER DE SOUZA WANDERLEY, PH.D., WHO IS STUDYING HOW DIFFERENT FACTORS IN THE TUMOR MICROENVIRONMENT IMPACT THE RESPONSE OF BRCA-MUTANT TUMOR CELLS TO PARP INHIBITORS, A TYPE OF TARGETED THERAPY FOR TREATING TUMORS WITH A BRCA MUTATION. THE GOAL OF THIS RESEARCH IS TO PROVIDE INSIGHT INTO POTENTIAL COMBINATION THERAPIES THAT WOULD IMPROVE THE RESPONSE TO PARP INHIBITORS. HARIKRISHNA NAKSHATRI, PH.D., FROM INDIANA UNIVERSITY, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE ADEDEJI. K. ADEBAYO, D.V.M., WHO WILL STUDY THE IMPACT OF OXYGEN EXPOSURE ON TUMOR CELLS DERIVED FROM TUMORS ACQUIRED FROM THE KOMEN TISSUE BANK AT THE INDIANA UNIVERSITY SIMON COMPREHENSIVE CANCER CENTER. THE GOAL OF THIS RESEARCH IS TO IDENTIFY HOW DIFFERENT OXYGEN CONDITIONS MODIFY TUMOR SIGNALING, GROWTH AND RESPONSE TO BREAST CANCER TREATMENTS. MARIA SOSA, PH.D., FROM ALBERT EINSTEIN COLLEGE OF MEDICINE, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER CAROLINA RODRIGUEZ TIRADO, PH.D., WHO WILL INVESTIGATE HOW THE PROTEIN ZFP296 ALLOWS DISSEMINATED, DORMANT CANCER CELLS TO FORM A METASTATIC TUMOR. THE GOALS OF THIS PROJECT ARE TO ILLUSTRATE THE ROLE OF ZFP296 IN REACTIVATING DORMANT CANCER CELLS, IDENTIFY POSSIBLE THERAPIES AGAINST ZFP296, AND ULTIMATELY, TO USE THESE FINDINGS TO HELP PREVENT BREAST CANCER METASTASIS. JUSTIN BALKO, PH.D., PHARM.D., FROM VANDERBILT UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT BRANDIE TAYLOR, WHO WILL INVESTIGATE WHY HETEROGENEOUS LEVELS OF THE PROTEIN MHC-I WITHIN A SINGLE TUMOR CAN NEGATIVELY IMPACT BREAST TUMOR RESPONSE TO IMMUNOTHERAPY. THESE STUDIES WILL LEAD TO AN INCREASED UNDERSTANDING OF WHY SOME TUMORS DON'T RESPOND TO IMMUNOTHERAPY. TASNEEM BAWA-KHALFE, PH.D., FROM THE UNIVERSITY OF HOUSTON, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO KACIE WAITERS, WHO WILL INVESTIGATE HOW THE MODIFICATION OF DNA VIA A PROCESS CALLED SUMOYLATION (SUMO) REDUCES TREATMENT EFFICACY AND DRIVES PROGRESSION OF BREAST TUMORS IN ADVANCED ENDOCRINE RESISTANT HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER. THE GOAL OF THIS STUDY IS TO DEMONSTRATE HOW SUMO IS INVOLVED IN THIS PROCESS AND TO EVALUATE AND PRODUCE NOVEL THERAPIES THAT WILL PREVENT TUMOR PROGRESSION. MICHELLE MARTINEZ-MONTEMAYOR, PH.D., FROM THE UNIVERSIDAD CENTRAL DEL CARIBE, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER LUZ V. ARROYO-CRUZ, PH.D., WHOSE STUDY WILL INVESTIGATE WHETHER A NATURAL STEROIDAL COMPOUND CAN TARGET SPECIFIC PROTEINS IN TUMOR CELLS, IMPAIRING THEM AND CAUSING THEM TO DIE, WITHOUT DAMAGING SURROUNDING HEALTHY CELLS. THE GOAL OF THIS STUDY IS TO DEMONSTRATE HOW THIS NATURAL COMPOUND CAN LEAD TO TUMOR CELL DEATH. MATTHEW BRADY, M.D., FROM THE UNIVERSITY OF CHICAGO, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT BRIANA BANKS FOR THIS RESEARCH, WHICH WILL DETERMINE WHETHER HIGHER LEVELS OF A STEROID HORMONE CALLED GLUCOCORTICOID (GC) MAY INCREASE THE RISK OF BREAST CANCER DURING CRITICAL TIMES OF DEVELOPMENT LIKE PUBERTY. USING PRECLINICAL MODELS OF BREAST CANCER, THEY WILL IDENTIFY HOW GC RELEASE AFFECTS THE DEVELOPMENT OF MAMMARY GLAND DUCTS AND DETERMINE WHETHER USE OF A GC-BLOCKING DRUG CAN REVERSE MANY OF THESE CHANGES THAT INCREASE BREAST CANCER RISK. CHRISTY HAGAN, PH.D., OF THE UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT HARMONY SAUNDERS, WHO WILL INVESTIGATE HOW PROGESTERONE TREATMENTS IMPACT BREAST CANCER. THIS STUDY WILL DETERMINE WHETHER ACTIVATION OF PROGESTERONE RECEPTORS IN THE MAMMARY GLAND ALLOWS TUMORS TO ESCAPE DETECTION BY THE IMMUNE SYSTEM AND AVOID CELL DEATH.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)</FormAndLineReferenceDesc>
        <ExplanationTxt>JULIE RHOADES, PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT LOGAN NORTHCUTT, WHO WILL INVESTIGATE HOW ESTROGEN RECEPTOR (ER) SIGNALING IS REGULATED WHEN TUMOR CELLS METASTASIZE TO THE BONE USING A NOVEL MODEL OF BONE STIFFNESS. THE INFORMATION GAINED FROM THIS STUDY WILL HELP RESEARCHERS UNDERSTAND HOW BREAST CANCER CELLS RESPOND TO ENDOCRINE THERAPY IN THE BONE, THE MOST COMMON SITE OF METASTASIS IN ER+ BREAST CANCER. ZACHARY T. SCHUG, PH.D., OF THE UNIVERSITY OF PENNSYLVANIA, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT DOCTORAL STUDENT KELSEY SALCIDO, WHO WILL INVESTIGATE THE RELATIONSHIP BETWEEN ALCOHOL CONSUMPTION AND BREAST CANCER RISK. BY DETERMINING WHETHER THE ACETATE FOUND IN ALCOHOLIC BEVERAGES SERVES AS A FUEL FOR TUMOR METABOLISM AND GROWTH. THE GOAL OF THIS STUDY IS TO IDENTIFY WAYS TO MITIGATE THE IMPACT OF ALCOHOL CONSUMPTION ON BREAST CANCER RISK. LEADERSHIP GRANTS: SCIENTIFIC ADVISORY BOARD MEMBER ALAN ASHWORTH, PH.D., OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, WILL IDENTIFY GENES THAT ALTER RESPONSE TO NEW FORMS OF IMMUNOTHERAPY CALLED CAR-T AND NK CELL THERAPY. THE GOAL OF THIS RESEARCH IS TO BRING NEW OPTIONS FOR IMMUNOTHERAPY TO PATIENTS WITH METASTATIC BREAST CANCER. KOMEN SCHOLAR DONALD MCDONNELL, PH.D., OF DUKE UNIVERSITY, RECEIVED FUNDS TO STUDY A PROTEIN CALLED LYPD3, WHICH IS ASSOCIATED WITH AGGRESSIVE BREAST CANCER. THROUGH THIS RESEARCH, DR. MCDONNELL HOPES TO DISCOVER NEW DRUGS FOR METASTATIC BREAST CANCER. KOMEN SCHOLAR, BEN H. PARK, M.D., PH.D., OF VANDERBILT UNIVERSITY MEDICAL CENTER, WILL INVESTIGATE WHY MUTATIONS IN THE SF3B1 PROTEIN CAUSE BREAST CANCER. BY UNDERSTANDING HOW THESE MUTATIONS CAUSE BREAST CANCER, DR. PARK HOPES TO IDENTIFY NEW STRATEGIES TO THERAPEUTICALLY TARGET BREAST TUMORS WITH SF3B1 MUTATIONS. SCIENTIFIC ADVISORY BOARD MEMBER LISA A. CAREY, M.D., SC.M., OF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, WILL INVESTIGATE HOW TUMORS DEVELOP RESISTANCE TO ANTIBODY- DRUG CONJUGATE (ADC) TREATMENTS. THE GOAL OF THIS RESEARCH IS TO IDENTIFY BIOMARKERS THAT INFORM ONCOLOGISTS HOW WELL A BREAST CANCER PATIENT'S TUMOR RESPONDS TO TREATMENT WITH ADCS KOMEN SCHOLAR DAWN HERSHMAN, M.D., OF COLUMBIA UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL TO DETERMINE IF INTERVENTIONS TO RELIEVE FOOD INSECURITY IMPROVES THE QUALITY OF LIFE FOR PATIENTS WITH METASTATIC BREAST CANCER THAT STRUGGLE WITH FOOD INSECURITY. THE GOAL OF THIS STUDY IS TO INVESTIGATE THE FEASIBILITY OF THESE INTERVENTIONS, WHILE PAVING THE WAY FOR A LARGER CLINICAL TRIAL THAT WILL INVESTIGATE HOW INTERVENTIONS TO RELIEVE FOOD INSECURITY IMPACT BREAST CANCER OUTCOMES. SCIENTIFIC ADVISORY BOARD MEMBER LISA NEWMAN, M.D., OF WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY, WILL STUDY THE GENETIC MAKEUP OF BREAST TUMORS FROM WOMEN OF AFRICAN ANCESTRY. THE GOAL OF THIS RESEARCH IS TO BETTER UNDERSTAND THE UNIQUE FEATURES OF THESE BREAST TUMORS TO ELIMINATE RACIAL DISPARITIES IN BREAST CANCER OUTCOMES. CHIEF SCIENTIFIC ADVISOR ANN PARTRIDGE, M.D., OF DANA-FARBER CANCER INSTITUTE, WILL INVESTIGATE UNIQUE BIOLOGICAL AND PSYCHOSOCIAL CHARACTERISTICS IN YOUNG WOMEN WITH BREAST CANCER. THE GOAL OF THIS RESEARCH IS TO IMPROVE TREATMENT OUTCOMES AND QUALITY OF LIFE FOR YOUNG WOMEN WITH BREAST CANCER WHO OFTEN EXPERIENCE GREATER DISTRESS THAN OLDER PATIENTS WITH BREAST CANCER. KOMEN SCHOLAR OLUFUNMILAYO OLOPADE, M.D., OF THE UNIVERSITY OF CHICAGO, WAS AWARDED A GRANT TO INVESTIGATE DIFFERENCES IN TREATMENT RESPONSE BETWEEN WHITE AND BLACK BREAST CANCER PATIENTS. BY PROVIDING A BETTER UNDERSTANDING OF HOW BLACK WOMEN'S TUMORS RESPOND TO TREATMENTS, THIS STUDY WILL HELP IMPROVE OUTCOMES IN THIS POPULATION. LEADERSHIP GRANTS - NEW KOMEN SCHOLARS: KOMEN SCHOLAR JEFFREY M. ROSEN, PH.D., OF BAYLOR COLLEGE OF MEDICINE, WILL STUDY HOW MACROPHAGES, A TYPE OF IMMUNE CELL, AFFECT TRIPLE NEGATIVE BREAST CANCER (TNBC). THE GOAL OF THIS STUDY IS TO IDENTIFY NEW MACROPHAGE-TARGETED IMMUNOTHERAPY DRUGS THAT COULD BE USED IN FUTURE CLINICAL TRIALS TO TREAT METASTATIC TNBC. KOMEN SCHOLAR BRYAN SCHNEIDER, M.D., OF INDIANA UNIVERSITY, WAS AWARDED A GRANT TO STUDY A TOXIC SIDE EFFECT FROM CHEMOTHERAPY THAT OCCURS MORE FREQUENTLY IN AFRICAN AMERICAN BREAST CANCER PATIENTS COMPARED TO OTHER POPULATIONS. THE GOAL OF THIS STUDY IS TO DECREASE THE DISPARITY IN SURVIVAL RATES FOR AFRICAN AMERICAN BREAST CANCER PATIENTS THROUGH PERSONALIZED MEDICINE. KOMEN SCHOLAR CARLOS ARTEAGA, M.D., OF THE UNIVERSITY OF TEXAS SOUTHWESTERN, WILL INVESTIGATE WHY SOME ER+ BREAST TUMORS BECOME RESISTANT TO CDK4/6 INHIBITORS. THE GOAL OF THIS STUDY IS TO CIRCUMVENT RESISTANCE TO THESE DRUGS TO IMPROVE OUTCOMES FOR PATIENTS WITH METASTATIC ER+ BREAST CANCER. KOMEN SCHOLAR MYLES BROWN, M.D., OF DANA-FARBER CANCER INSTITUTE, WILL STUDY HOW BREAST TUMORS FORM USING CUTTING-EDGE RNA SEQUENCING TECHNIQUES. THROUGH UNDERSTANDING THE FORMATION OF BREAST TUMORS, DR. BROWN HOPES TO UNCOVER NEW THERAPEUTIC TARGETS FOR BREAST CANCER PREVENTION KOMEN SCHOLAR SUSAN DOMCHEK, M.D., OF THE UNIVERSITY OF PENNSYLVANIA, WILL INVESTIGATE NEW STRATEGIES FOR HELPING WOMEN WITH BRCA1 AND BRCA2 MUTATIONS MAKE DECISIONS REGARDING BREAST CANCER SCREENING AND RISK-REDUCING SURGERY. THE GOAL OF THIS PROJECT IS TO CAPITALIZE ON NEW ADVANCES IN GENETIC TESTING TECHNOLOGY TO EMPOWER PATIENTS TO MAKE THE BEST DECISIONS FOR THEIR BREAST HEALTH. KOMEN SCHOLAR DAVID MANKOFF, M.D., PH.D., OF THE UNIVERSITY OF PENNSYLVANIA, WAS AWARDED FUNDS TO STUDY NEW APPLICATIONS OF PET MOLECULAR IMAGING IN BREAST CANCER. FROM THESE STUDIES, DR. MANKOFF EXPECTS TO IMPROVE DIAGNOSTIC CAPABILITIES FOR ALL BREAST CANCERS, BUT PARTICULARLY FOR THOSE DIFFICULT TO DETECT WITH CURRENT TECHNOLOGY, SUCH AS INVASIVE LOBULAR BREAST CANCER. KOMEN SCHOLAR HARIKRISHNA NAKSHATRI, PH.D., OF INDIANA UNIVERSITY, WILL STUDY A PROTEIN CALLED TONSL THAT IS ABNORMALLY INCREASED IN BREAST TUMORS AND LEADS TO RESISTANCE OF PARP INHIBITORS, THE TREATMENT OF CHOICE FOR PATIENTS WITH BRCA1/2 GENE MUTATIONS. THE GOAL OF THIS RESEARCH IS TO IDENTIFY DRUGS THAT TARGET TONSL THAT CAN BE USED IN PATIENTS WITH BRCA1/2 MUTATIONS WHOSE TUMORS DEVELOP RESISTANCE TO PARP INHIBITORS. KOMEN SCHOLAR KATHY MILLER, M.D., OF INDIANA UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL THAT WILL TEST WHETHER BLACK WOMEN BENEFIT FROM A NEW DRUG COMBINATION DESIGNED TO DECREASE HEIGHTENED INFLAMMATION THAT IS OFTEN OBSERVED IN BREAST CANCER IN BLACK WOMEN. AS BLACK WOMEN ARE 40% MORE LIKELY TO DIE FROM BREAST CANCER THAN WHITE WOMEN, THIS TRIAL HAS THE POTENTIAL TO CLOSE THE GAP OF THIS DISPARITY AND IMPROVE THE POOR OUTCOMES THAT BLACK WOMEN FACE. KOMEN SCHOLAR, ANTONIO WOLFF, M.D., OF JOHNS HOPKINS UNIVERSITY, WILL CONDUCT A CLINICAL TRIAL EVALUATING THE OPTIMAL STRATEGY FOR TREATING TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS WITH IMMUNOTHERAPY. THE GOAL OF THIS RESEARCH IS TO ENSURE THAT PATIENTS WITH NEWLY DIAGNOSED TNBC RECEIVE IMMUNOTHERAPY AT THE RIGHT TIME, IN AN OPTIMIZED FASHION. MBC COLLABORATIVE RESEARCH INITIATIVE KATHERINE REEDER-HAYES, M.D., OF UNIVERSITY OF NORTH CAROLINA CHAPEL-HILL AND DEVON CHECK, PH.D., OF DUKE UNIVERSITY ARE COLLABORATING ON A RESEARCH STUDY AS PART OF THE MBC-COLLABORATIVE RESEARCH INITIATIVE. THEY WILL WORK TOGETHER TO INCREASE OUR UNDERSTANDING OF THE KEY SOCIAL DETERMINANTS OF HEALTH (SDOH) OF METASTATIC BREAST CANCER (MBC) DEVELOPMENT AND OUTCOMES THROUGH RECRUITING A DIVERSE GROUP OF WOMEN LIVING WITH MBC TO INVESTIGATE HOW CHRONIC STRESS, INFLAMMATION AND IMMUNE SYSTEM CHANGES IMPACT BLACK AND WHITE WOMEN WITH MBC TO IMPROVE PATIENT OUTCOMES. OPPORTUNITY GRANTS: ANTONIO WOLFF, M.D., OF JOHNS HOPKINS UNIVERSITY, WILL RECEIVE FUNDING TO SUPPORT THE TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM (TBCRC). THE TBCRC, A GROUP OF 19 CLINICAL SITES, PROVIDES A FORUM WHERE INVESTIGATORS, ADVOCATES, COORDINATORS, SCIENTISTS AND BIOSTATISTICIANS WORK TOGETHER TO PLAN AND REFINE CLINICAL TRIALS, ADVANCING BREAST CANCER KNOWLEDGE MORE EFFICIENTLY ACROSS THE FIELD. MORE THAN HALF OF TBCRC TRIALS HAVE FOCUSED ON METASTATIC BREAST CANCER. MELISSA TROESTER, PH.D., OF THE UNIVERSITY OF NORTH CAROLINA, WILL RECEIVE FUNDING TO CONTINUE THE CAROLINA BREAST CANCER STUDY, INTEGRATING CLINICAL, BIOLOGICAL, AND SOCIAL INFORMATION TO DETERMINE HOW DISPARITIES ARISE ACROSS MULTIPLE LEVELS, FROM THE BIOLOGY OF THEIR TUMORS TO THE FACTORS, THAT IMPACT THEIR CARE WITHIN THEIR COMMUNITIES. THESE STUDIES WILL IDENTIFY INTERVENTIONS THAT IMPROVE OUTCOMES AND CLOSE THE RACIAL GAP IN BREAST CANCER SURVIVAL FOR BLACK WOMEN.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)</FormAndLineReferenceDesc>
        <ExplanationTxt>MICHELE COTE, PH.D., OF INDIANA UNIVERSITY (IU), WILL RECEIVE FUNDING TO SUPPORT A PARTNERSHIP BETWEEN THE SUSAN G. KOMEN TISSUE BANK (KTB) AND KOMEN'S BIG DATA FOR BREAST CANCER (BD4BC) INITIATIVE, A PROGRAM DESIGNED TO EXPLORE THE POWER OF BIG DATA FOR ADVANCING RESEARCH AND IMPROVING BREAST CANCER PATIENT CARE AND OUTCOMES. THIS GRANT WILL SUPPORT THE COLLECTION AND STORAGE OF SALIVA FOR PATIENT-DRIVEN RESEARCH. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE ABOUT BREAST CANCER AND PORTIONS OF THE PATIENT &amp; CAREGIVER SECTIONS OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER CANCER INSTITUTE STAFF, RECEIVED MORE THAN 3 MILLION PAGE VIEWS DURING FY23. KOMEN USED THE CLINICAL TRIALS INITIATIVE ON KOMEN.ORG TO EDUCATE PEOPLE ABOUT THE ROLE CLINICAL TRIALS, INCLUDING THOSE FROM UNDER- REPRESENTED POPULATIONS, AND EMPOWERING PEOPLE WITH INFORMATION ON TRIALS AND RESOURCES, WITH PERSONALIZED SUPPORT AVAILABLE THROUGH THE KOMEN BREAST CARE HELPLINE. THE RESOURCES HELP TO ENSURE PATIENTS ARE EQUIPPED TO MAKE INFORMED DECISIONS REGARDING TRIAL PARTICIPATION IN PARTNERSHIP WITH THEIR HEALTH CARE PROVIDERS. THE INITIATIVE ALSO RAISES AWARENESS OF THE DIFFERENT TYPES OF TRIALS, INCLUDING TRIALS SUPPORTED BY KOMEN, FOCUSED ON RISK, SCREENING AND EARLY DETECTION, TREATMENT, FAMILY SUPPORT, QUALITY OF LIFE AND SURVIVORSHIP. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACT SHEETS, AND C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS. IN ADDITION, IN FY23 KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 12 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH. WE OFFER ON-DEMAND VIDEOS OF THESE EVENTS IN BOTH ENGLISH AND SPANISH FOR THOSE NOT ABLE TO ATTEND LIVE. THE MBC IMPACT SERIES ALSO OFFERS REGULAR NEWSLETTERS AND QUARTERLY WELLNESS WEDNESDAY VIDEOS FOCUSED ON QUALITY OF LIFE AND OVERALL WELLNESS TOPICS. PATIENT SUPPORT WIDESPREAD BARRIERS TO CARE CONTRIBUTE TO POOR OUTCOMES AND DEATH FROM BREAST CANCER. THESE BARRIERS INCLUDE SOCIOECONOMIC FACTORS, A LACK OF ACCESS TO CARE AND INFORMATION, AND DISCRIMINATION IN HEALTH CARE AND QUALITY OF CARE. SUSAN G. KOMEN'S PATIENT CARE CENTER (PCC) PROVIDES INDIVIDUALIZED CARE TO HELP ENSURE THE BEST POSSIBLE OUTCOMES FOR EVERY PERSON IN NEED OF SUPPORT THROUGHOUT THEIR BREAST CANCER JOURNEY. OUR TEAM OF CULTURALLY RESPONSIVE NAVIGATORS PROVIDED MORE THAN 42,000 SERVICES TO OVER 30,000 PEOPLE THIS YEAR, INCLUDING: * ANSWERS TO QUESTIONS ABOUT BREAST CANCER RISK. * EMOTIONAL SUPPORT AND GUIDANCE IN ADDRESSING FEELINGS AND OTHER CONCERNS. * INFORMATION ABOUT BREAST CANCER SCREENING, TREATMENT OPTIONS, CLINICAL TRIALS, SUPPORT RESOURCES, AND GENETIC COUNSELING AND TESTING. * ACCESS TO NO-COST SCREENING MAMMOGRAMS AND DIAGNOSTIC SERVICES BASED ON INCOME ELIGIBILITY. * FINANCIAL ASSISTANCE FOR INCOME-ELIGIBLE BREAST CANCER PATIENTS IN TREATMENT OR LIVING WITH METASTATIC BREAST CANCER. * NAVIGATING THE HEALTH CARE SYSTEM, INCLUDING COMMUNICATING WITH HEALTH CARE PROVIDERS, UNDERSTANDING TREATMENT OPTIONS AND ACCESSING SUPPORT SERVICES. THE KOMEN PCC TEAM IS MADE UP OF MORE THAN 50 HIGHLY SKILLED PROFESSIONALS WHO ARE AS DIVERSE AS THOSE WE SERVE . OUR CARING AND COMPASSIONATE TEAM INCLUDES ONCOLOGY SOCIAL WORKERS, BILINGUAL SPECIALISTS, SUBJECT MATTER EXPERTS AND BREAST CANCER SURVIVORS FROM AROUND THE COUNTRY WHO UNDERSTAND THAT EVERYONE'S HEALTH CARE JOURNEY IS UNIQUE, THUS PROVIDING INDIVIDUALIZED CARE TO ENSURE THE BEST POSSIBLE OUTCOMES FOR EACH PERSON. METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE KOMEN LAUNCHED THE METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE (MBCCRI) WITH A PILOT PROGRAM AT DUKE UNIVERSITY AND THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. THE GOAL IS TO CATALYZE AND SUPPORT MULTI-INSTITUTIONAL RESEARCH COLLABORATIONS AND BRING TOGETHER THE BEST AND BRIGHTEST RESEARCHERS AT SELECT INSTITUTIONS TO SHARE IDEAS, EXPERTISE AND RESOURCES. KOMEN WILL SUPPORT RESEARCH GRANT TO FIND BREAKTHROUGH DISCOVERIES TO END METASTATIC BREAST CANCER. INFLAMMATORY BREAST CANCER COLLABORATIVE FOR THE FIRST TIME, KOMEN IS LEADING TO DRIVE A NEW DIAGNOSTIC DEFINITION OF BREAST CANCER, SPECIFICALLY INFLAMMATORY BREAST CANCER, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN HAS PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO CONVENE PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE CARE OF IBC PATIENTS. A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES IS BEING VALIDATED. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH AND CLINICAL CARE. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE OF MORE THAN 4 MILLION BREAST CANCER SURVIVORS AND THOSE LIVING WITH THE DISEASE IN THE U.S. AS WELL AS THE PEOPLE WHO LOVE THEM. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THE CENTER FOR PUBLIC POLICY IS THE CORNERSTONE OF KOMEN'S MISSION, TO END BREAST CANCER FOREVER, THROUGH SOUND PUBLIC POLICY AND ADVOCACY COUPLED WITH SCIENTIFIC PROGRESS AND PATIENT SUPPORT SERVICES DESIGNED TO OVERCOME BARRIERS TO CARE. THE CENTER FOR PUBLIC POLICY IS THE DRIVING FORCE THAT ENSURES THE VOICE OF BREAST CANCER PATIENTS, SCIENTISTS, HEALTH CARE PROFESSIONALS, CAREGIVERS, AND ENGAGED MEMBERS OF THE PUBLIC WILL BE HEARD BY GOVERNMENT REGULATORS ON LOCAL, STATE AND NATIONAL LEVELS. KOMEN BELIEVES THAT ONLY THROUGH INFORMED GOVERNMENT ACTION CAN BROAD, SYSTEMIC AND LASTING CHANGES BE MADE TO PROTECT BREAST CANCER PATIENTS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)</FormAndLineReferenceDesc>
        <ExplanationTxt>KOMEN'S 2022-2023 PUBLIC POLICY AND ADVOCACY PRIORITIES INCLUDED: EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED EDUCATION, UTLIZATION OF AND ACCESS TO CLINICAL TRIALS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; AND ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR PUBLIC POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROTHESES, GENETIC AND GENOMIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Line 1a Executive Committee</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Line 11b Review of form 990 by governing body</FormAndLineReferenceDesc>
        <ExplanationTxt>MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Line 12c Conflict of interest policy</FormAndLineReferenceDesc>
        <ExplanationTxt>KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, DIRECTOR, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, EMPLOYEE, AND VOLUNTEER TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR INTERNAL AUDIT, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN REQUIRES ALL BOARD MEMBERS, OFFICERS, DIRECTORS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW AND EXECUTE THE CONFLICT OF INTEREST POLICY ANNUALLY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Line 15a Process to establish compensation of top management official</FormAndLineReferenceDesc>
        <ExplanationTxt>THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Line 15b Process to establish compensation of other employees</FormAndLineReferenceDesc>
        <ExplanationTxt>THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Line 19 Required documents available to the public</FormAndLineReferenceDesc>
        <ExplanationTxt>KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part IX, Line 1</FormAndLineReferenceDesc>
        <ExplanationTxt>FOR NEARLY 40 YEARS, SUSAN G. KOMEN HAS WORKED TO FULFILL ITS VISION OF CREATING A WORLD WITHOUT BREAST CANCER THROUGH ITS MISSION OF SAVING LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO BETTER DETECT, PREVENT, TREAT BREAST CANCERS. OVER THE LAST THREE YEARS, KOMEN CONTINUED TO IMPLEMENT A SERIES OF CHANGES BEGUN IN 2020 TO STRENGTHEN ITS FINANCIAL AND OPERATIONAL POSITION IN RESPONSE TO THE CHANGING NEEDS OF THE BREAST CANCER COMMUNITY AND ECONOMIC CONDITIONS RESULTING FROM THE COVID-19 PANDEMIC. KOMEN HAS NEARLY COMPLETED THE CONSOLIDATION OF ALL OPERATIONS OF ITS INDEPENDENT AFFILIATES INTO ITS HEADQUARTERS ORGANIZATION, RESULTING IN A SINGLE ORGANIZATION. THIS CONSOLIDATION IS ENABLING KOMEN TO LEVERAGE THE COMBINED EXPERTISE OF ITS MISSION LEADERS TO DELIVER A UNITED MISSION PROGRAM, UTILIZING TECHNOLOGY AS A KEY DRIVER TO CONNECT TO PEOPLE WHO NEED TO ACCESS CARE WHERE THEY ARE AND TO HELP IMPROVE THE PATIENT EXPERIENCE, AS WELL AS RESULTED IN ADMINISTRATIVE AND OPERATIONAL EFFICIENCIES. CENTRAL TO KOMEN'S VISION IS A STEADFAST COMMITMENT TO INVESTING IN BREAKTHROUGH RESEARCH. KOMEN REMAINED COMMITTED TO INVESTING IN RESEARCH CENTERED ON THE PRIMARY FOCUS OF METASTATIC BREAST CANCER AND UNDERSTANDING AND ELIMINATING DISAPARITIES IN BREAST CANCER OUTCOMES BETWEEN BLACK AND WHITE PATIENTS. DESPITE THE ECONOMIC UNCERTAINTY AND CHALLENGING FUNDRAISING ENVIRONMENT, KOMEN AWARDED $40 MILLION IN NEW RESEARCH AWARDS OVER THE PAST TWO FISCAL YEARS. WHILE WE CONTINUE TO INVEST IN RESEARCH INTO NEW TREATMENTS, KOMEN SUPPORTS PEOPLE WHO ARE FACING BREAST CANCER TODAY THROUGH A GROWING SUITE OF PATIENT CARE SERVICES, INCLUDING DIRECT FINANCIAL ASSISTANCE THROUGH ITS TREATMENT ASSISTANCE PROGRAM, ELIGIBLE TO HELP PAY FOR EXPENSES THAT MAY SERVE AS A BARRIER TO ATTAINING THE CARE NEEDED TO SURVIVE, SUCH AS CO-PAYS, TRANSPORTATION, CHILDCARE OR RENT.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part XI, Line 9 Other changes in net assets or fund balances</FormAndLineReferenceDesc>
        <ExplanationTxt>RESCINDED GRANTS - 1101560; Program COGS - -32562;</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>
